初创公司尽调
尽调报告 Robotics / Retail Automation Late-stage private 2026-07-06

Galaxy Bot

Galaxy Bot (Galbot):战略背书强、已有真实部署,但经济性仍不透明

Galaxy Bot 是一家战略上可信的中国具身 AI 机器人公司,已有真实部署证据,资本背书也少见地深;但单位经济性不透明、合作伙伴集中,承销仍偏投机。

封面要素

最近披露融资 01
RMB 2.5B (~$350M) [CI005]
已披露融资总额 02
~$1.15B+ USD [CI006]
最新披露估值 03
3000 USD M [CI004]
Series B 里程碑 04
$153M led by CATL [CO014]
成立时间 05
2023-05-19 [CO004]
总部 06
Beijing, China [CO003]

公司概况

Galaxy Bot 公开品牌为 Galbot,是一家 2023 年 5 月成立、总部位于北京的具身 AI 机器人公司。公开资料把公司定位在通用移动操作和类人形零售、工业、医疗流程上,场景包括库存处理、补货、包装、药房运营和工厂自动化。 公司把研究驱动的具身 AI 与实际机器人部署经验结合起来,并获得 CATL 以及之后带国资背景的中国资本战略背书。到 2026 年,公开报道显示 Galaxy Bot 已明显越过 2025 年 6 月 $153 million Series B 里程碑,但收入基础和单元经济仍未公开。

官网
www.galbot.com
成立时间
2023-05-19
创始人
He Wang, Yao Tengzhou
创立地点
Beijing, China
总部
Beijing, China
产品
Galaxy Bot 的产品叙事围绕面向零售、工业和医疗环境的具身 AI 机器人展开;公开资料重点呈现库存管理、补货、配送、包装和高精度制造用例。
客户
制造、零售和医疗领域的企业及机构买方,中国是核心运营市场,CATL 是最显眼的战略对手方之一。
商业模式
可能由硬件销售、部署与集成费用,以及经常性服务或托管运营收入混合构成;公开证据尚未确认是否单独披露软件或模型授权收入线。
阶段
Late-stage private
融资情况
公开证据显示,公司在 2025 年 6 月由 CATL 领投完成 $153 million Series B 里程碑,2025 年 12 月又以 $3 billion 估值完成 $300+ million 融资,2026 年 3 月获得国家人工智能产业投资基金领投的 RMB 2.5 billion 融资,使截至 2026 年的累计已披露资本约为 $1.15 billion+。
[CO001, CO003, CO004, CO005, CO009, CO014, CI004, CI005]

执行摘要

主要优势

  • CATL 及后续国资背景投资人背书,提升了制造可信度、采购通道和续航能力。
  • 公开提到的零售、工业和医疗部署表明,Galaxy Bot 不只是停在演示阶段。
  • 具身 AI 定位和科研联系,让公司比不少纯硬件机器人同行更有技术可信度。

主要风险

  • 收入、毛利率、回本周期和服务成本数据未披露,单位经济性还没有被证明。
  • 客户和融资集中在 CATL 等头部伙伴周围,可能扭曲外界对牵引力的判断,也带来治理风险。
  • 人形或具身 AI 系统的监管、安全和信任要求收紧很快,公开合规成熟度证据跟不上。
  • 估值相对公开披露大幅扩张;如果部署不能转化成可重复商业需求,执行风险会放大。

未决问题

  • 收入、毛利率和现金消耗历史
  • 单次部署 ROI 和回本周期
  • 与 CATL 及其他标杆客户的合同结构和集中度
  • 员工规模、服务组织规模和现场支持经济性
  • 产品安全事故历史和正式合规证据

目录

Chapter 01

01公司概览

1.1 身份、品牌与运营版图

Galaxy Bot 看起来与如今公开以 Galbot 品牌示人的公司是同一业务;部分英文来源也称其为 Galaxy General Robot。相较摘要数据库,尽调中最重要的修正是官网:当前官方入口指向 galbot.com,而不是提示中给出的、看起来偏旧的 galaxybot.ai。官网称公司是具身 AI 与通用机器人开发商,并展示商业零售、工业制造和医疗应用。Baidu Encyclopedia 汇总的工商登记式信息显示,法律实体为 Beijing Galbot Co., Ltd. / Beijing Galaxy General Robot Joint Stock Co., Ltd.,地址在北京市海淀区,成立于 2023 年 5 月 19 日。这与独立报道相互印证:公司在 2025 年 6 月完成 CATL 领投融资时,多次被称为一家约两岁的北京创业公司。 相比稀疏的渲染 HTML,官方 Web 应用包透露了更多信息。它显示 Galbot 在北京、深圳、苏州、香港设有研发中心,并与 Peking University、Xuanwu Hospital、Beijing Zhongguancun College 建立了联合实验室或研究中心。这些细节很关键,因为公司不只是一个纯概念阶段的人形机器人创业公司,更像一个研究商业化平台,试图同时搭建模型和部署渠道。同一批官方资料把商业与零售用例描述为精准拣选、配送、库存管理和补货,与 Crunchbase 对“用于库存、补货和包装的人形机器人”的描述相吻合。 身份层面缺失的信息同样重要。本次审阅没有找到任何公开一手来源披露经审计财务、准确员工数或权威董事会名单。公司显然希望外界把它当作广义具身智能平台,而不是单一门店零售机器人供应商;但在有更充分的独立披露之前,投资者应谨慎看待规模说法,尤其是活跃机器人数量、已上线站点数量,以及现有安装究竟是试点、付费生产部署还是展示环境。[CO001, CO002, CO003, CO004, CO007, CO008]

快照 KPI 表
指标数值 / 状态日期 / 期间置信度缺口或注意事项
已验证运营品牌Galbot / Galaxy General Robot2026提示 URL 不一致;当前官方网页入口是 galbot.com,而不是 galaxybot.ai
法律实体 / 注册Beijing Galaxy General Robot Joint Stock Co., Ltd.(前称 Beijing Galbot Co., Ltd.)2023-2025需获取中国工商登记导出,确认最新注册英文译名
成立时间2023-05-192023由 Baidu 式登记摘要支持;未审阅单独 SAMR 摘录
总部中国北京海淀区当前公开来源确认北京;尽调包还需登记摘录确认准确邮寄地址
当前阶段Series B / 战略成长阶段2025-06Series B 之后的融资只得到部分独立佐证
最近一次独立锚定融资RMB 1.1 billion(约 $153 million)2025-06独立媒体佐证了金额;具体交割机制未公开
独立估值锚$1 billion2025-06后续 $3 billion 估值来自公司口径,需要确认
研发布局北京、深圳、苏州、香港当前未披露各站点员工数或支出
收入 / 运行收入未公开披露2026要求提供管理账和客户发票
员工数未公开披露2026要求提供当前组织架构图和薪资汇总
零售部署证明约 10 家北京门店获独立报道;后续声称覆盖 >30 个城市2025-2026需拿到实时客户 / 门店清单,以对齐试点与规模铺开

本表将独立佐证事实与公司声称的后期规模断言拆开,并标出未披露指标。

[CO003, CO004, CO007, CO014, CO015, CO025]
FO002: 公司快照逻辑

Galaxy Bot 目前的叙事,是用战略资本和合作伙伴,把学术模型开发接到零售和工业部署上。

[CO007, CO008, CO009, CO018, CO020, CO023]
FO003: 披露支撑的快照 KPI

最干净的公司概览指标,应把成立、融资、部署证据和披露缺口放在一起,而不是重复快照表。

[CO004, CO014, CO017, CO025, CO040]

1.2 创始人、管理层与治理

公开创始人证据最强地指向一个双人运营核心:He Wang 负责研究和模型侧,Yao Tengzhou 负责商业化和机器人产业侧。Peking University 的教师主页确认,He Wang 是 CFCS 预聘制助理教授,2021 年获 Stanford 博士学位、师从 Leonidas Guibas,并担任 PKU-Galbot 具身 AI 联合实验室主任。Galbot 官网嵌入的团队内容同样把他呈现为公司背后的标志性科学人物。这让 Galaxy Bot 在具身 AI 创业公司中拥有异常强的创始人—市场匹配:首席技术创始人是仍在一线研究的学者,具备深厚的 3D 视觉、机器人学习和抓取履历,而不是从相邻软件市场转入的纯运营者。 Baidu Encyclopedia 的公司和创始人条目补上了运营侧人物。条目称 Yao Tengzhou 为联合创始人和法定代表人,描述其毕业于 Beihang 机器人研究所,并曾在 ABB 上海机器人研发中心工作。这个背景与公司的商业命题一致:把前沿机器人学习研究,与务实的硬件设计、制造和部署经验拼在一起。Baidu 还称 Guo Xiaoliang 为董事长,说明公司在扩张并于 2025 年底完成股份制改革后,治理正式化程度可能已超出两位创始人的小核心。 不过,以机构投资者标准看,治理透明度仍偏薄。审阅来源没有提供清晰的公开董事名单、投票结构或投资人权利摘要。这对当前阶段的中国民营机器人公司并不罕见,但会提高尽调对管理层访谈的依赖。后续投资人会议应要求公司提供当前股权结构、董事会构成、保留事项,以及 CATL、Puquan Capital、Meituan、Bosch 关联实体或国资基金是否持有可能影响战略、采购或退出时点的特殊治理权。[CO004, CO005, CO010, CO011, CO012, CO013]

领导层与创始人表
人物角色背景创始人-市场匹配 / 职能覆盖关键人依赖
He Wang创始人 / 首席技术人物Peking University 助理教授;Stanford PhD,导师 Leonidas Guibas;PKU-Galbot 联合实验室主任掌握具身 AI 研究可信度、模型架构和学术招聘管线高 — 技术愿景和研究品牌集中在他身上
Yao Tengzhou联合创始人 / 法定代表人Beihang Robotics Institute 毕业;曾在 ABB Shanghai 从事机器人研发带来机器人产品化、硬件工程和商业化经验高 — 从研究走向可部署产品的重要桥梁
Guo Xiaoliang董事长Baidu 公司档案称,公司扩张和改制后由其担任董事长代表公司越过创始期后的治理正规化中 — 角色细节和权限边界未公开披露
PKU-Galbot Joint Lab研究治理节点联合实验室把公司开发与 Peking University 研究生态连接起来把人才漏斗和科学合法性延伸到典型创业公司实验室之外中 — 有用的机构支持,但不能替代商业治理

覆盖范围限于公开具名的创始人和领导层信号。已审阅来源没有提供完整董事会名单或投资人权利摘要。

[CO004, CO005, CO010, CO011, CO012, CO013]

1.3 资本结构与战略支持方

公开融资证据在 2025 年 6 月这一轮最扎实。Crunchbase 的独角兽榜单文章称 Galaxy Bot 获 Contemporary Amperex Technology 领投 $153 million,估值 $1 billion。独立机器人和行业媒体随后补充轮次细节:The Robot Report、Ofweek、Exportsemi、Robotics & Automation News 均称公司完成 RMB 1.1 billion 融资,由 CATL 和 Puquan Capital 领投,China Development Bank 的科技基金、Beijing Robot Industry Fund 以及其他中国风险投资人参与。合在一起,这些来源足以支撑一个高置信结论:Galaxy Bot 在 2025 年中越过独角兽门槛,CATL 是关键战略支持方。 这个投资人组合的战略价值至少与估值标题同等重要。CATL 不只是财务出资方;到 2026 年 6 月,独立媒体 CNEVPost 和 Gasgoo 报道称,双方签署战略合作协议,Galbot S1 机器人已进入 CATL 生产线。Bosch 关联资本是第二个值得关注的锚点。GlobeNewswire 和多家机器人媒体报道,Boyuan Capital、Bosch China 与 Galbot 设立合资公司并签署 MOU,重点面向工业制造应用。这让 Galaxy Bot 获得两条特权商业化走廊:EV 电池制造和高精度工业自动化。 在此之上,还有一个更激进、但置信度更低的增长故事。2025 年 12 月,Galbot 通过 PR Newswire 发布新闻稿,称完成超过 $300 million 融资、估值达到 $3 billion;The Robot Report 也复述了这些公司说法。由于这次后续估值跃升高度依赖公司端披露,而非广泛独立佐证,本章把 2025 年 6 月 CATL 领投轮和 $1 billion 估值作为最清洁、外部锚定的资本事实,同时将之后的 $3 billion 数字标记为可信但尚未达到尽调级。[CO014, CO015, CO016, CO017, CO018, CO019]

利益相关方或投资人图谱
利益相关方角色公开证据控制 / 经济重要性尽调问题
CATL主要战略投资人和工业伙伴领投 2025 年 6 月融资;2026 年 6 月签署战略合作关键 — 融资、电池和制造部署渠道都在这里交汇确认董事席位权利、商业排他性和所有采购挂钩里程碑
Puquan Capital共同领投 / CATL 相关资本平台在 2025 年融资报道中与 CATL 并列出现高 — 可能在财团组建和后续支持中重要厘清持股比例,以及权利是否映射 CATL 的经济权益
China Development Bank 科技基金国资背景投资人融资报道将其列为新投资人高 — 增加政策协同和耐心资本要求确认具体工具、所有政策条件和后续跟投权利
Beijing Robot Industry Fund地方战略投资人在 2025 年融资和后续产业资本报道中出现高 — 城市级生态支持和潜在试点项目入口厘清市政支持绑定的部署预期
Meituan 战略投资早期战略投资人Baidu 年表称 Meituan 参与 2023 Angel+ 融资中 — 潜在零售分发和消费者服务邻近性确认是否存在活跃 Meituan 相关试点或数据共享安排
Boyuan Capital / Bosch China合资及工业商业化伙伴GlobeNewswire 和机器人媒体宣布 2025 年 6 月 JV 与 MOU高 — 创造零售之外的工业商业化选项审阅 JV 治理、IP 归属和地域权利

本图谱聚焦公开可见的战略利益相关方,而不是完整资本结构表。准确持股比例、清算优先权和治理权利未公开。

[CO014, CO015, CO016, CO018, CO019, CO020]
FO001: 公司里程碑时间线

Galaxy Bot 从成立到拿下独角兽级融资大约用了两年,中间陆续叠加技术模型发布和产业合作。

[CO004, CO014, CO018, CO020, CO023, CO024]

1.4 里程碑、规模信号与未解问题

对一家 2023 年成立的公司来说,Galaxy Bot 的运营推进异常快。Baidu 的公司年表指向一连串节点:2023 年天使融资,2024 年 Peking University 联合实验室和第一代机器人发布,2025 年 1 月 GraspVLA,2025 年 3 月智能零售方案,2025 年 6 月 Bosch 关联 JV,2026 年 6 月 CATL 战略生产线合作。The Robot Report 2025 年中的报道把 G1 描述为轮式双臂移动操作机器人,用于自动化库存、补货、配送和包装;当时已在北京近 10 家门店部署,并计划年内覆盖全国 100 家门店。后续与公司有关的报道进一步推高了规模说法,称 Galbot Store 覆盖 30 多个城市,公司已拿到数千台订单。 技术叙事足以解释投资人热情。ArXiv 论文显示 GraspVLA 和 TrackVLA 是真实发表的技术项目,NVIDIA 也记录 DexGraspNet 是 Galbot 构建的大型仿真灵巧抓取数据集。这支持一个判断:公司不只是集成现成机器人硬件,而是在尝试搭建一套自有具身模型栈,覆盖抓取、追踪和零售任务执行。这种差异化很重要,因为不少人形机器人竞争者仍依赖吸睛演示,而不是面向特定领域的任务学习。 即便如此,最审慎的概览仍应以谨慎收尾。KR Asia、MERICS 以及 U.S.-China Economic and Security Review Commission 都强调同一个宏观风险:商业化仍早、成本仍高、精度和自主性仍有限,投资者也越来越担心人形机器人估值跑在收入之前。就 Galaxy Bot 而言,收入、毛利率、烧钱速度、准确员工数、客户集中度,乃至试点转为生产部署的比例,都没有公开证据。这些缺口不否定公司的技术动能,但也意味着,叙事中最有吸引力的部分在能力层面比在成熟财务层面更有证据。[CO018, CO020, CO021, CO022, CO023, CO024]

里程碑表
日期事件类型金额 / 状态参与方 / 含义
2023-05公司在北京成立创立已成立启动 Galbot / Galaxy General 品牌背后的法律实体
2023-11Angel+ 融资引入包括 Meituan 在内的战略投资人融资数亿元人民币(公司年表)显示早期商业验证和生态赞助
2024-05PKU-Galbot 具身智能联合实验室揭牌合作运营中的研究合作把学术研究与创业公司产品化之间的桥制度化
2024-06第一代 Galbot G1 公开亮相产品发布里程碑推动公司从研究叙事走向可部署零售机器人叙事
2025-01GraspVLA 发布产品基础模型里程碑释放公司认真投入具身模型 IP 的信号
2025-03面向无人门店的智慧零售解决方案发布规模化零售试点运营启动围绕盘点、补货和包装创造首个清晰商业用例
2025-06-17Boyuan Capital / Bosch China JV 与 MOU 发布合作JV + 工业 MOU把投资论点从零售扩展到高精度制造
2025-06-23CATL 领投的 RMB 1.1 billion 轮融资完成融资~$153 million;独立报道估值 $1 billion跨过独角兽门槛,并加深与 EV 产业的联系
2025-11股份制改制完成,公司名称更新治理股份制结构暗示公司为更机构化的融资和治理正规化做准备
2025-12公司称新一轮 $300M+ 融资估值达 $3B融资公司口径,部分获佐证估值可能大幅上台阶,但仍需要更强独立验证
2026-06CATL 生产线合作公开宣布规模化S1 进入 CATL 智能产线工业部署越过演示的最强独立信号
2026行业级投资人公开质疑人形机器人商业化经济性反向外部质疑升温给估值耐久性和融资动能带来背景风险

日期结合公司年表、独立融资报道和战略合作报道;2025 年 12 月融资上台阶的置信度仍低于 2025 年 6 月那一轮。

[CO004, CO014, CO018, CO020, CO023, CO024]

1.5 图表

Chapter 02

02市场分析

2.1 市场边界与现状替代方案

Galaxy Bot 的正确市场框架应窄于“所有人形机器人”,又宽于“门店里的机器人”。Galbot 声称要完成的任务——库存盘点、补货、拣选、配送和包装——触及三个已经存在的自动化池:零售自动化、服务机器人和仓储 / 物流机器人。中国 2024 年社会消费品零售总额达到 48.79 trillion yuan,其中实物商品网上零售额为 13.08 trillion yuan,占总额 26.8%。这很关键,因为零售商决定是否自动化门店劳动力时,不只是把 Galaxy Bot 与人工员工对比;它还会与自助结账、智能购物车、电子价签、条码 / RFID 流程、自主移动机器人,甚至向电商履约迁移的渠道方案对比。换句话说,相关预算分散在门店运营、IT、设施和供应链自动化里,而不是一个清晰的“人形机器人”科目。 相邻市场数据强化了这一点。仅中国自助结账市场,2024 年规模就估算约 $330 million,2035 年将达 $1.3 billion;全球仓储机器人已经是数十亿美元级品类,全球服务机器人规模更大。这些市场用更低的技术野心解决同一运营问题的一部分。想加快结账、减少前端收银员的食品杂货商,可以安装自助结账或智能购物车。想做重复搬运和配送的零售商或药房,可以用轮式服务机器人。3PL 或电商仓库可以投 AMR、AGV 或拣选系统。只有当移动操作机器人或人形形态在受限物理环境中的多任务表现明显优于这些替代品时,Galaxy Bot 才能赢。 这种边界逻辑会影响估值。公司可以引用万亿美元级人形机器人预测,但如果近端客户预算要与便宜得多的点状方案竞争,实际可服务市场就是零售和履约劳动力支出的过滤子集。因此,本章把零售自动化、自助结账、服务机器人、仓储机器人和电商替代,一并纳入同一条买方决策树。[CM001, CM002, CM003, CM004, CM005, CM006]

市场定义表
细分 / 品类纳入支出排除 / 邻近支出买方 / 付款方与 Galaxy Bot 的相关性
人形机器人 / 移动操作零售自动化店内拣选、补货、货架任务、店内跑腿配送、包装、药房服务工作流纯软件分析、智能购物车、仅自助结账系统、固定亭机门店运营、创新团队、设施、连锁管理当一台机器人能替代多项人工任务时,这是核心目标切入口
服务机器人酒店 / 餐饮、配送、导引、运输、专业服务机器人人形机器人专属灵巧度或多臂操作主张运营团队、医疗 / 酒店运营商、商业设施重要邻近市场,也是成本更低的替代集合
仓储 / 物流机器人拣选、分拣、运输、码垛、料箱移动、履约自动化前场客户互动和结账3PL 运营、仓库经理、供应链资本开支邻近工作流池,与同一套节省人工论点竞争
自助结账 / 智能购物车 / 无人零售结账人工替代、更快交易、购物篮可见性、前端客户吞吐后场拣选、全店补货、复杂操作零售 IT、门店运营、财务门店劳动力问题的一部分,有更便宜的替代方案
电商与全渠道替代线上订单获取、履约、点击自提、店内数字 / 线下整合实体人形机器人劳动自动化本身数字商务、履约、全渠道领导层零售商可能选择渠道迁移或仓库自动化,而不是门店人形机器人

边界由买方面临的问题定义——在维持客户体验的同时降低门店和履约人工——而不是由某一种机器人形态定义。

[CM001, CM002, CM003, CM004, CM005, CM006]
FM003: 围绕 Galbot 目标任务的替代技术图谱

Galaxy Bot 的真正竞争对象不是「没有自动化」,而是一组更窄的自动化方案;它们从不同角度争抢同一笔人力预算。

[CM001, CM003, CM004, CM005, CM006, CM039]

2.2 市场测算口径与估计分散

人形机器人市场测算异常不稳定,因为分析师常常在量不同的东西:有人只统计硬件收入,有人把软件和服务也纳入,还有人建模的是长期劳动力替代,而不是近端销售。Morgan Stanley 的长期观点最乐观之一:预计到 2050 年全球将有近 1 billion 台人形机器人,约 90% 用于工业或商业场景,仅中国潜在在用量就可达 302.3 million 台。Goldman Sachs 也乐观,但仍有条件:一份被引用的报告称,10 到 15 年内市场至少 $6 billion;如果产品设计、可负担性和公众接受度障碍被克服,2035 年蓝天情景可达 $154 billion。相较之下,Interact Analysis 认为,尽管理论可寻址市场有 $2 trillion,实际全球人形机器人出货到 2032 年可能只有约 40,000 台、约 $2 billion 收入。 中国特定估计同样不清爽。一家市场研究来源称,中国人形机器人市场将从 2025 年约 $173.5 million 增至 2034 年 $1.69 billion;另一家称其 2024 年为 $205 million,到 2032 年接近 $5.93 billion;China Daily 引用会议估算称,2024 年为 2.76 billion yuan,到 2029 年达 75 billion yuan。差距太大,不能机械求平均。真正的洞见恰恰是分散本身:市场足够真实,能吸引资本和政策关注,但方法论仍不成熟,且高度依赖假设。 做尽调时,更可信的办法是把自上而下 TAM 口径,与已经存在的近邻市场配对——仓储机器人、服务机器人、自助结账和零售自动化——再进一步收窄到移动操作机器人能创造增量 ROI 的预算子集。因此,一个干净的章节应保留相互矛盾的估计,而不是把它们抹平,因为分歧正是当下市场的核心特征。[CM006, CM008, CM009, CM012, CM013, CM014]

TAM/SAM/SOM 或规模测算视角表
发布方 / 视角基准年预测年份 / 数值CAGR / 增长视角方法 / 范围说明置信度 / 限制
Goldman Sachs 人形机器人(基础 / 蓝天情景)n/a10-15 年内至少 $6B;蓝天情景到 2035 年 $154B情景驱动全球人形机器人市场,假设障碍可能被克服也可能未被克服中 — 情景框架,不是近期实现需求
Morgan Stanley 人形机器人2024 成本基线到 2050 年接近 1B 台;约 90% 工业 / 商业;中国 302.3M 台长期装机基座模型全球装机基座和价格下降论点,而不只是近期收入中 — 有用的长期信号,近期精度弱
Interact Analysis 谨慎情形2025 可触达市场前提到 2032 年约 40,000 台、约 $2B 收入障碍压制采用全球现实情形收入 / 出货,尽管理论 TAM 大得多高,适合警示用途;刻意保守
DeepMarketInsights 中国人形机器人2025: $173.54M2034: $1.69B28.45% CAGR中国人形机器人市场,涵盖零售、工业、医疗应用低-中 — 私营市场研究方法不透明
DataBridge 中国人形机器人2024: $205M2032: $5.93B70.81% CAGR中国人形机器人市场,增长假设激进得多低-中 — 轨迹高度激进;用作矛盾视角
China Daily / 会议估算2024: RMB 2.76B2029: RMB 75B隐含极陡增长官方媒体报道的会议估算;工业制造被框定为领先用例低-中 — 存在宣传偏向,且与 USD 来源单位不匹配
MarketsandMarkets 服务机器人2024: $47.10B2029: $98.65B15.9% CAGR覆盖多场景和多应用的全球服务机器人市场中 — 品类口径宽,不专指 Galbot
Fortune Business Insights 仓储机器人2025: $6.51B2034: $25.41B16.80% CAGR全球仓储机器人市场,需求主要由电商拉动中 — 相邻市场,不是零售人形机器人的直接支出
中国自助结账零售2024: $330M2035: $1.30B13.27% CAGR中国自助结账替代市场中低 — 替代技术视角,不是人形机器人 TAM

本章有意保留相互矛盾的估算,因为不同供应商和分析师对市场边界和方法论的选择差异很大。

[CM005, CM009, CM012, CM015, CM016, CM017]
FM001: 相邻自动化市场增长率对比

预测增速最高的是最具投机性的人形机器人估算;相邻替代市场装机基数更大,增长更稳。

[CM005, CM009, CM027, CM028, CM030]

2.3 买方、预算所有者与采用路径

Galbot 的买方分层最好按工作流理解,而不是按机器人分类。大卖场和超市关心上架准确率、门店劳动生产率、结账吞吐和损耗管理。便利店和药房关心 24/7 轻人力运营、补货,以及小面积场地里的服务速度。餐饮和酒店经营者更在意重复配送和服务支撑,而不是拟人能力。仓库和 3PL 关心能否安全、低成本地移动商品、周转箱和纸箱。工业制造商关心结构化重复任务,因为这些场景机器人利用率高、流程环境可预测。每个细分市场都有不同的使用者、付费方和接受门槛。 市场给出的最重要采用经验是:规模化商业化迄今最先出现在结构化环境里。Agility Robotics 和 GXO 称,双方在试点后签署了首个正式商业人形机器人部署和首个 RaaS 人形机器人协议,Digit 在真实物流作业中搬运周转箱。China Daily 的行业报道从中国侧给出同样判断:工业制造被视为首个主要人形机器人应用领域,因为其标准化程度高,也更容易约束环境。这对 Galbot 是有意义的信号。虽然公司的零售故事有吸引力,但更广泛的买方证据仍支持仓库、物流和工业场景,胜过高变化、面向顾客的门店环境。 零售还面临严酷的替代集合。Amazon 从 Fresh 门店撤下 Just Walk Out,转向智能购物车,以保留便利性并让购物者实时看到账单。这很重要,因为它说明,即便资金充足的零售自动化实验,也会在客户信任、经济性或运营透明度崩塌时重新设计。实践中,门店自动化预算可能先流向更简单的方案;人形机器人或移动操作机器人只会留给那些场所:一台设备能替代多套更窄系统,或在药房、小型门店、混合零售履约等难招人的业态里实质降低劳动力。[CM005, CM006, CM007, CM017, CM026, CM029]

细分市场 / 买方地图
细分市场买方使用者付款方 / 预算负责人工作流采用触发因素
大卖场 / 超市区域门店运营负责人门店员工和部门经理门店运营 + 零售 IT + 财务货架补货、前端吞吐量、库存准确性大店型需要更高用工效率,也要客服体验稳定
便利店 / 药房连锁管理层、加盟运营商、药房运营店员、药剂师、理货员运营 + 设施 + 创新预算小店型补货、取货、7x24 小时辅助服务城市密集网点排班难,劳动力覆盖紧
餐饮 / 酒店服务餐厅运营和场地管理服务人员运营 / 门店总经理级运营支出送餐、收台、引导、前场重复性支持需要提速,并减少重复搬运
仓库 / 3PL / 履约自动化或供应链负责人仓库员工物流运营下的资本开支或 RaaS周转箱搬运、拣选、分拣、运输结构化环境、重复任务下 ROI 清晰
工业制造工厂自动化和工程团队产线员工工厂资本开支 / 自动化预算物料搬运、检测、装配辅助环境标准化,利用率高,产出可衡量

买方地图看重工作流和预算归属,而不是机器人形态;早期商业化证据在结构化物流和工业场景最强。

[CM004, CM005, CM006, CM007, CM017, CM026]
FM002: 零售和履约机器人买家采用路径

结构化环境从试点走向规模部署更快,因为 ROI 和安全边界更容易界定;面向消费者的零售场景更慢。

[CM017, CM026, CM034, CM035, CM039, CM040]

2.4 需求驱动、约束与 Galbot 含义

中国显然具备支撑自动化需求的宏观条件。2023 年机器人密度达到每 10,000 名制造业员工 470 台,高于 2022 年的 402 台,位居全球第三,仅次于韩国和新加坡。机器人产业“十四五”规划目标是年收入增速超过 20%,并到 2025 年将工业机器人使用密度翻番。与此同时,中国劳动年龄人口占比 2023 年降至 61.3%,2025 年启动的退休年龄改革将逐步把男性从 60 岁推至 63 岁,女性从 50/55 岁推至 55/58 岁。这些变化不保证人形机器人一定被采用,但确实强化了政策和劳动力背景,支持更多自动化支出。 但市场约束是具体且短期的。Interact Analysis 强调安全、灵巧性、成本和形态不确定性;仓储机器人研究强调前期投资高、维护负担重;服务机器人研究指出隐私、互操作性和标准化问题;劳动力市场研究显示,当员工面临工资或就业压力时,自动化会引发政治和组织阻力。VoxDev 的中国证据尤其重要,因为它把风险讨论从理论拉到可测量的劳动结果:机器人暴露降低了受影响群体的就业概率和工资,同时把劳动者推向再培训或提前退休。 对 Galaxy Bot 而言,市场吸引力不取决于宏观 TAM 话术,而取决于能否在受限用例中证明任务级 ROI。最佳早期切入点,是中国友好的自动化政策环境与严重劳动力压力重叠之处,并且多用途移动操作机器人能做得比自助结账亭、服务机器人或 AMR 更多。最不应过度投入的地方,是宣称所有零售环境都已准备好迎接人形机器人。市场在增长,资本充裕,战略投资人已参与——但商业证明仍必须跑赢热度。[CM010, CM011, CM012, CM013, CM014, CM023]

增长驱动因素与约束表
因素方向机制证据对 Galaxy Bot 的含义
劳动年龄人口收缩驱动劳动力减少,企业更愿意关注提升生产率的自动化2023 年劳动年龄人口占比降至 61.3%支撑长期自动化需求,尤其是用工紧张业态
退休年龄改革混合驱动提高劳动参与率,同时也暴露结构性老龄化和养老金压力男性逐步提高至 63 岁;女性提高至 55/58 岁自动化需求仍有支撑,但紧迫性因细分市场而异
中国机器人政策支持驱动产业规划、标准工作和收入增长目标,降低生态建设风险“十四五”规划目标为年增长 >20%,机器人密度翻倍国内机器人公司的供应商基础和政策顺风更强
高机器人密度和制造基础驱动现有自动化生态降低零部件、集成和学习成本2023 年中国每 10,000 名制造业工人拥有 470 台机器人先利好工业和物流落地,再进入更复杂的零售场景
安全性和灵巧度限制约束人形机器人可能跌倒,操作能力仍吃力,很多任务的生产率低于人类Interact Analysis 将安全性和灵巧度列为主要障碍若不把用例约束清楚,难以在门店大范围部署
资本强度和维护负担约束机器人有 ROI 预期,但前期投入和全生命周期支出都高仓储和服务机器人资料都强调初始投资和维护成本高买方会先转向试点、RaaS 或更便宜的替代品
替代技术约束自助结账、智能购物车、服务机器人和仓储 AMR 能更便宜地解决部分问题Amazon 下线 Just Walk Out,同时自助结账市场继续增长Galbot 必须证明多任务优势,而不是泛泛证明自动化价值
融资热度 vs PMF约束在具身 AI 里,资本可能跑在收入验证前面Yicai 报道融资狂热,但尚无已验证的大规模商业应用估值上行空间存在,但市场进入纪律很关键

驱动因素和约束有意成对呈现,因为大多数正向采用力量也伴随执行、政治或 ROI 风险。

[CM008, CM010, CM011, CM012, CM013, CM023]
FM004: 市场信号 KPI

最相关的市场信号,应同时看宏观用工压力、自动化密度、数字化替代和资本流入。

[CM002, CM003, CM013, CM043]

2.5 图表

Chapter 03

03竞争对手

3.1 竞争格局与真正重要的玩家

不能只拿几家知名人形机器人品牌来给 Galbot 做基准。真实格局包括:直接的全栈人形机器人同行,汽车支持或上市公司入场者,可能抽象掉硬件差异的模型层竞争者,固定自动化与人工零售或工厂劳动力等替代品,以及能借汽车或电子生态供应链规模切入的潜在进入者。在直接具身 AI 竞争里,AgiBot 和 Unitree 最重要,原因是它们已有中国出货证据;Figure 最重要,原因是资本强度和全球叙事能力;Physical Intelligence 也重要,因为如果通用机器人基础模型能跨硬件迁移,它可能压缩产品差异化。相邻压力来自 XPENG、UBTech、Boston Dynamics 和 1X,各自切入工业、商业或家庭机器人中的不同切片。现实中的现状替代品仍是人工劳动力加任务专用自动化,这让买方审查继续聚焦可靠性和劳动力替代,而不只是人形新奇感。[CP001, CP002, CP004, CP006, CP009, CP012]

竞争格局
竞争对手总部成立时间阶段融资估值产品关键客户 / 垂直领域部署状态
Galbot中国北京2023私营成长期累计披露 $1.15B+最新披露 $3BG1 具身 AI 机器人平台工业、零售、医疗健康已披露工厂、医院部署,零售覆盖 30+ 城市
AgiBot中国上海2023私营成长期未披露未披露A2、G1、X2、D1 人形及四足产品线工业自动化 OEM 平台引用来源称,2025 年出货 5,100 台,2026 年 3 月生产第 10,000 台机器人
Unitree中国杭州2016私营后期或 IPO 前未披露未披露G1、H1 人形机器人及四足机器人研究、开发者、工业试点声称全球出货至 30+ 国家,并公开 G1 标价
Figure AI美国2022私营后期C 轮已承诺资本 >$1B$39B 投后估值Figure 01、02、03,搭载 Helix 和 BotQ用工自动化和未来家庭市场商业与家庭路线图,叠加制造扩张
Physical Intelligence美国2024私营模型公司未披露未披露π0 和 π0.5 通用机器人模型跨硬件模型层在 8 款机器人上验证软件模型,并开源发布
XPENG IRON中国广州上市公司项目上市公司既有玩家母公司出资母公司公开市场估值IRON 人形机器人加 VLA 2.0 技术栈零售导览、出行和汽车相邻机器人目标 2026 年底量产,2027 年 Q1 起用于门店
UBTech Walker S1中国深圳上市公司上市成长期上市公司融资公开市场估值Walker S 系列人形机器人工业和服务机器人计划 2026 年 5,000 台、2027 年 10,000 台

表格整合公司声明和独立报道中的融资、估值及部署信号;多个竞争对手不披露可比融资或估值数据,因此空白反映的是披露缺口,而非没有资本支持。

[CP002, CP004, CP006, CP009, CP010, CP012]
FP001: 竞争对手定位象限

按当前商业证据和与 Galbot 当前逻辑的直接重合度,对主要同业做序数映射。

X 和 Y 位置是基于引用证据综合出的 1–10 序数判断,不是已发布的市场份额或收入数据。

[CP004, CP009, CP012, CP014, CP021, CP026]

3.2 高信号竞争者画像

AgiBot、Unitree、Figure 和 Physical Intelligence 代表四种不同竞争者原型。AgiBot 是最清晰的中国规模同行:它结合了广泛硬件组合、激进生产里程碑,以及一个超越单一机器人本体的 OEM 平台叙事。Unitree 是最清晰的公开价格锚,也是最显眼的低端商业化故事,G1 价格低得多,并拥有广泛国际发货覆盖。Figure 是资本最充裕的风险投资支持基准,把醒目估值与面向劳动力和家庭场景的制造及模型栈叙事绑定在一起。Physical Intelligence 与其说是直接硬件卖方,不如说是模型层风险;它的通用 π0 系列和开源发布,让人更容易想象未来硬件会变得更可替代。XPENG 和 UBTech 是重要的快速跟随者,因为它们带来汽车或公开市场资源;但当前承销压力最大,仍来自中国规模组合以及美国资本 / 模型组合。[CP002, CP003, CP004, CP005, CP006, CP007]

市场进入和定价对比
竞争对手价格区间部署模式目标客户渠道验证状态
Galbot企业定价未披露直接部署和集成工厂、零售商、医院国资关联投资者和已披露企业客户标识已披露多站点部署,但无公开 ASP
AgiBot未披露硬件加 Powered by AgiBot OEM 平台工业客户和 OEMCES 首秀和国内规模化推进出货证据强,但经济性未披露
Unitree公开 G1 锚点价格 $13,500机器人销售,全球发货研究、开发者和轻量商业用途线上品牌触达和 30+ 国家同业中公开价格透明度最好
Figure AI未披露企业部署和未来家庭市场推广商业运营方和家庭风险投资网络和战略投资者资本和路线图已验证,定价未公开
Physical Intelligence开源和模型驱动软件和模型分发机器人开发者和实验室openpi 仓库和研究社区模型验证强,但直接变现不够清晰
XPENG未披露母公司渠道商业化推出零售和出行相关用户汽车品牌和零售渠道路线图公开,但规模化交付仍在未来

定价对比为方向性判断,因为除 Unitree 外公开标价很少;多数同业的买方比较重点是合同模式、渠道强度和验证成熟度,而不是逐项可比的单机标价。

[CP007, CP010, CP014, CP023, CP024, CP027]
FP003: 融资 / 估值格局

头部资本和估值基准,塑造了竞争耐力叙事。

图表混合展示估值和资本基准,因为只有部分同业同时披露两者;目的在于呈现耐力不对称,而不是逐项可比的企业价值比较。

[CP010, CP020, CP030]

3.3 能力、定价、GTM 与信任对比

能力对比的核心不是原始演示有多吸睛,而是谁能把操作、导航、部署成熟度和企业集成装进同一个方案。Galbot 公开的技术栈异常垂直:它声称自有数据、模型、硬件,以及一组用于抓取、导航和零售工作流的 VLA。AgiBot 和 Figure 最像 Galbot,都试图同时掌握本体和智能层;Unitree 在公开入门价上更透明;Physical Intelligence 作为通用软件抽象最强。GTM 上,Galbot 与 CATL、Mercedes-Benz、Zeekr、医院以及多城市零售版图的具名部署,指向一种由企业客户牵引、依赖标杆账户和政策入口的销售方式,而不是消费者或研究主导漏斗。信任姿态也很关键:尤其在监管和责任框架追上工厂、医院和公共零售空间中的人形机器人使用时,买方会比看重基准测试视频标题更重视具名部署、安全信号和标准对齐。[CP018, CP019, CP020, CP021, CP023, CP024]

能力对比矩阵
维度GalbotAgiBotUnitreeFigurePhysical Intelligence
技术栈掌控数据、模型、硬件自研本体加平台架构硬件牵引,配控制栈本体、模型和制造栈覆盖第三方机器人的模型层
公开核心差异点GraspVLA、TrackVLA、GroceryVLA 加 Sim2Real一个机器人本体,三种智能低成本公开人形机器人锚点Helix VLA 加 BotQ通用 π0 基础模型
操作成熟度零售和工厂演示较强产品族宽,但公开任务细节参差不齐公开移动能力和基础操作验证较好操作能力叙事聚焦用工场景取决于接入的机器人本体
导航或自主性TrackVLA 和多站点运营OEM 平台定位公开运动能力强家庭和劳动力场景自主性路线图强调跨平台泛化
部署成熟度已披露工厂、医院和门店高出货量主张出货覆盖广,但企业客户披露较少叙事声量高,但公开规模细节较少软件成熟,但缺少直接部署规模
价格透明度none

矩阵为定性判断,只反映所给来源明确支持的内容,不是实验室基准排名;价格透明度为低或无,意味着公开定价有限或缺失。

[CP007, CP011, CP018, CP019, CP020, CP024]
FP002: 竞争能力柱状图

基于公开证据,从技术栈深度、部署和自主性三个维度,对竞争者能力宽度做指数化对比。

分数是 0–100 归一化综合指标,来自技术栈所有权、部署成熟度和公开产品宽度的定性证据。

[CP007, CP011, CP012, CP018, CP020, CP024]

3.4 切换成本、锁定与分销不对称

Galbot 的护城河不是经典软件网络效应;它是一组运营捆绑:数据集深度、站点集成、客户工作流调优,以及采购渠道入口。当客户在真实门店、医院或工厂验证部署后,这会创造有意义的切换成本,但并不会让多供应商并行变得不可能。如果人形机器人本体收敛到相似的 VLA 架构和任务 API,客户可能同时测试不止一家供应商,再按可靠性、支持质量和经济性分配任务。因此,分销变得异常重要。Galbot 的国资支持投资人组合,以及与工业龙头的关系,可能提高它进入中国试点项目、建立采购可信度和获得伙伴引荐的能力,这是规模更小、只有风投资本的创业公司很难匹配的。另一方面,不对称也会反过来:XPENG 等拥有汽车或电子供应链的在位者,或其他大型制造商,如果人形机器人品类变得更由规模而非模型驱动,可能在制造杠杆上追平甚至超过 Galbot。[CP021, CP022, CP027, CP033, CP034, CP035]

护城河评估
护城河维度Galbot 评估耐久度关键风险
数据集规模10B+ 数据点主张支撑学习闭环优势对手可能很快积累可比具身数据
垂直技术栈掌控自研硬件加 VLA 技术栈降低依赖Figure 和 AgiBot 也走类似全栈打法
已披露企业部署工业、零售、医疗健康均有较强验证中高部署可能仍以试点为主,尚未深度规模化
渠道和政策准入国资背景投资方可能改善采购准入政策优势可能局限在国内,也可能被大型既有玩家追平
定价权公开 ASP 和服务经济性未披露,因此不清晰更便宜或资本更厚的同业可能挤压利润率
架构独特性Sim2Real 加面向任务的 VLA 目前看有差异化VLA 商品化可能迅速侵蚀独特性

耐久度标签是基于截至 2026-06-14 已披露证据的承销判断;不是数字化市场份额预测。拿到胜负单和定价数据后应重新审视。

[CP019, CP021, CP022, CP025, CP030, CP034]

3.5 护城河耐久度与反向情景

Galbot 的反向情景不是没有竞争者,而是强竞争者太多,且同时存在:它们都有重叠的 VLA 叙事,却都还未完整证明广泛买方愿意付费。外部批评仍很尖锐。TechXplore 引述观察人士称,许多人形机器人仍是表演性大于功能性,真实用例仍很窄。市场领导权说法也很嘈杂:AgiBot 在部分 2025 出货数据集中排名第一,但 Unitree 用自己的出货说法质疑这一领先地位。最后,中国估值基准仍远低于 Figure 等美国同行,这意味着即便部署叙事看似可比,资本市场仍在折价中国人形机器人玩家的耐久度或全球变现能力。最稳妥的判断是:Galbot 在中国本土部署入口和垂直栈所有权上确有近端护城河;但除非它能证明经济性更好、学习循环更快、真实世界利用率高于正奔向同一架构的竞争对手,否则长期护城河耐久度只有中等。[CP029, CP030, CP031, CP032, CP034, CP036]

3.6 图表

Chapter 04

04财务

4.1 收入模型、定价与确认问题

Galbot 的公开商业故事暗示了几条收入流,尽管公司没有披露完整财务拆分。最显眼的是 G1 平台硬件销售,但这类销售很可能与集成工作、部署配置和支持承诺打包出现,使设备收入与实施服务之间的界线变得模糊。第二条收入流出现在零售和药房运营中,Galbot Store 和药房部署更像运营商或托管服务模式,而不是一次性产品销售。CATL、Mercedes-Benz 以及 Bosch 关联伙伴的工业项目,意味着更大的企业合同和更长验收周期;医疗部署则带来服务质量和可靠性义务,可能让收入确认时点更复杂。同样重要的是缺口:Galbot 没有披露 ASP、合同期限、任何门店经济性是否基于收入分成,以及软件或模型授权是否与硬件分开入账。因此,收入模型在形态上可读,但真实组合和会计处理仍不透明。[CI008, CI009, CI010, CI011, CI012, CI013]

收入模式与定价
收入流定价单位经济性代理指标规模化成熟度置信度
硬件销售企业 ASP 未披露单次部署的名义合同金额可能最大真实存在但不透明
工业部署与集成按项目或里程碑定价ACV 更高,但周期更长,且有验收风险真实存在,并由具名客户佐证
维护与支持未披露续费附加收入可稳定生命周期价值很可能存在,但未单独量化
Galbot Store 运营不清楚:运营方、托管服务,还是收入分成劳动力替代和门店吞吐量是核心价值代理指标商业化可见,但会计口径不清
医疗与药房自动化未披露可靠性和受监管流程可能支撑溢价服务收入新兴垂直场景
数据集或模型授权公开资料未证实若属实,可抬高软件利润率仅属推测

收入流根据部署描述和公开产品界面推断;Galbot 未发布正式收入结构、定价表或收入确认政策。

[CI008, CI009, CI010, CI011, CI012, CI013]
定价与变现表
项目公开定价信号备注置信度
G1 机器人价格未披露Galbot 硬件没有公开 ASP
Galbot Store 经济性未披露可见运营方或托管服务逻辑,但未标价
工业部署费用未披露很可能按场地和工作流逐项目议价
医疗部署定价未披露可靠性要求指向溢价服务范围
外部价格锚点Unitree G1 标价 $13,500可作为低端价格背景,但不能与 Galbot 直接比较

投资人最需要定价透明的地方,公开可见性反而最弱;本表把 Galbot 缺失的价格披露与外部市场锚点分开。

[CI008, CI009, CI013, CI014]

4.2 GTM 方式与销售效率代理指标

Galbot 的 GTM 看起来由企业销售和标杆账户驱动,而不是自助式。公开进展通过具名部署、战略投资人关系,以及工厂、医院和零售环境中的案例式叙事浮现,意味着高接触销售、更长试点,以及比软件式产品驱动增长更复杂的实施。这可以是优势,因为大型工业和医疗客户能创造信任和可复制性;但也意味着销售效率只能从代理指标推断。公开证据显示,Galbot 正围绕劳动力替代或吞吐经济性优化:据称一台机器人能运营 50 平方米门店,并在三年内替代三班人力;医院药房流程则引用 99.5% 处理成功率。这些数据点支持价值创造,但没有披露 CAC、回本周期、留存或扩张。GTM 含义是,Galbot 可能拿下高 ACV 客户,但投资者仍缺少判断获客是否高效、可复制,并且轻资本到足以支撑当前融资规模的指标。[CI010, CI015, CI016, CI017, CI018, CI019]

单位经济性代理指标
指标数值/估计来源置信度
单台机器人覆盖门店面积每台机器人 50 平方米Galbot JS bundle 与二级资料复核
劳动力替代代理指标三年三班制Galbot JS bundle 与二级资料复核
年度劳动力价值代理指标按 $15/小时、满负荷计算,每年 ~$131K基于劳动力替代说法的外部测算
药房处理成功率99.5%ChinaTechNews
工业订单累计数千台China Daily 和公司相关报道
毛利率区间20-40% 有可能,但未经验证仅为行业背景

这些都是代理指标和背景锚点,不是经审计的经济性;劳动力价值行是明确的外部估计,毛利率区间是品类启发式判断,而非 Galbot 披露。

[CI017, CI018, CI019, CI020, CI023, CI034]

4.3 成本结构、利润率驱动与资本强度

Galbot 的成本结构几乎肯定比软件投资者直觉上想象的更偏硬件。一次人形机器人部署会嵌入物料清单成本、机电组件、电池、传感器、算力、工厂人工、现场安装和持续服务支持。这意味着毛利率不仅由定价权决定,也由良率、利用率、保修负担和服务效率支配。公开来源没有披露 Galbot 毛利率,但更广泛的物理 AI 和机器人背景显示,其利润率区间很可能远低于纯 SaaS,并取决于制造成熟度。营运资本也是可能的拖累:尤其当企业买方协商按里程碑付款时,机器人和零部件必须先通过库存和部署周期融资,现金才能完全回收。2026 年 3 月融资很可能正是为这些压力供血——制造爬坡、模型开发和现场部署扩张——因此,Galbot 应按资本密集型物理 AI 公司来承销,而不是按轻资产 AI 软件供应商。[CI022, CI023, CI024, CI025, CI026, CI027]

FI002: 财务画像条形图

指数化财务画像,显示当前尽调中 Galbot 最强和最弱的位置。

分数是归一化到 0–100 的定性尽调指数,不代表经审计财务比率。

[CI013, CI020, CI023, CI026, CI029, CI032]

4.4 公开进展真实,但财务披露偏薄

Galbot 的公开进展在运营层面亮眼,在财务层面薄弱。运营侧,来源指向 2025 年底 30 多城零售覆盖、2026 年初 100 多个药房或门店部署、累计数千台工业订单,以及药房流程中非常具体的任务成功率说法。这足以判断 Galbot 不是只停留在实验室的创业公司。但如果没有订单到交付的转化、合同金额、验收时点或服务绑定细节,这些指标都无法干净地转化为已入账收入。公司不披露收入、ARR、EBITDA、毛利率、烧钱速度或客户集中度。即便利用率或劳动力替代叙事很强,仍只是代理指标,不是已确认财务结果。因此,更合适的框架是不对称:部署证据有意义,但收入质量仍未经验证,因为公开章节呈现运营远多于会计。[CI017, CI019, CI020, CI021, CI032, CI033]

财务缺口台账
指标公开可得缺口描述置信度尽调要求
收入未披露年度收入或 ARR要求提供按垂直场景和季度拆分的月度确认收入
毛利率未披露按产品或服务线拆分的毛利率要求提供单位经济性和毛利率桥接
EBITDA 或经营亏损未披露盈利能力或烧钱速度要求提供管理账和现金流摘要
客户集中度有具名客户标识,但没有收入集中度数据要求提供前 10 大客户收入占比和积压订单
CAC 与回本周期企业销售动作可见,但缺少效率指标要求提供漏斗、销售周期和回本数据
订单转化部分资料提到数千台订单,但交付节奏未知核对订单、已验收台数和确认收入
现金余额与续航期累计融资公开,但当前现金未披露要求提供银行余额、烧钱速度和未来运营计划

该台账区分运营证明和财务证明;许多标杆部署说法公开可见,但承销所需的会计指标仍属私有。

[CI013, CI016, CI021, CI026, CI027, CI028]
FI003: 财务披露 KPI 快照

压缩展示哪些信息已公开披露,哪些仍需尽调。

[CI004, CI006, CI020, CI032]

4.5 资本充足性与融资依赖

从资本充足性看,Galbot 在民营创业公司标准下很强。融资路径从 2023 年未披露的种子轮和天使轮,升级到 2025 年 6 月 RMB 1.1B 机构轮,再到 2025 年 12 月以 $3B 估值完成超过 $300M 融资,之后 2026 年 3 月 RMB 2.5B 融资把累计已披露资本推至约 $1.15B+。这种资本规模应给予 Galbot 充足空间,在没有迫近融资悬崖的情况下扩张制造、商业部署和模型训练。两个保留项是烧钱速度和融资依赖。烧钱未披露;对于一家研发和现场运营都很重的人形机器人公司,烧钱可能相当可观。融资依赖也不只是数字问题,而是战略问题:国家资本和产业资本已经参与,让 Galbot 看起来比许多创业公司风险更低;但同样的支持也可能把预期锁向国内战略目标。总体看,资本充足性不错,但在现金和烧钱披露前,跑道仍只是估计。[CI001, CI002, CI003, CI004, CI005, CI006]

融资轮次时间线
轮次日期金额领投方总融资额估值关键条款
种子轮2023-06-01未披露未披露未披露未披露公开机构轮前的创始融资
天使轮2023-08-01未披露未披露未披露未披露早期天使融资,公开资料未披露金额
天使+轮2023-10-01未披露未披露未披露未披露2024 年规模化前的过桥融资
机构成长轮2024-03-01数亿 RMB(估计)未披露公开资料未对齐未披露首个主要机构轮;公开金额仍为约数
CATL 领投轮2025-06-25RMB 1.1B (~$153M)CATL Capital / Puquan Capital隐含累计 ~$500M独角兽(>$1B)跟投方包括 China Development Bank、Beijing Robotics Industry Fund、Granite Asia
新一轮融资2025-12-01>$300M投资方来自中国、新加坡和中东累计融资 ~$800M$3B资金用于扩大部署和具身 AI 研发
国家 AI 基金轮2026-03-02RMB 2.5B (~$350M)National AI Industry Investment Fund(Phase III,国家 AI 产业投资基金)累计融资 ~$1.15B+未单独披露跟投方包括 Sinopec、CITIC Investment Holdings、Bank of China、SAIC Financial Holdings

早期轮次公开披露但未披露金额,2024 年 3 月轮次仍是媒体估算;后续行采用公司和新闻来源披露的金额与累计融资额。

[CI001, CI002, CI003, CI004, CI005, CI006]
FI001: 融资瀑布图

示意从早期融资累加到 Galbot 2026 年 3 月后近似累计资本基础。

早期轮次和 2024 年 3 月数字为估算,因为只有后续轮次公开了金额;该图旨在呈现量级,不是经审计的累计募资额。

[CI001, CI002, CI004, CI005, CI006]
FI004: 资本强度 / 现金流图谱

融资如何转化为制造和部署,以及仍待回答的现金效率问题。

这张流图抽象了从融资到运营的桥接关系;现金余额、烧钱速度和营运资本周转仍未披露。

[CI007, CI024, CI025, CI026, CI028, CI036]

4.6 财务结论与尽调问题

Galbot 的财务图景结合了强资产负债表代理指标与弱披露质量。看多情景很直接:公司已融到足够多的钱,有能力成为重要玩家;跨多个垂直领域拥有可信部署参考;并且似乎是在战略支持而非资金绝境中,同时投入制造和具身 AI 研发。看空情景同样清楚:投资者仍无法验证收入、毛利率、烧钱速度、回本周期、客户集中度,甚至无法验证硬件、服务和运营商收入之间的拆分。这很关键,因为该品类已经面临真实买方需求质疑,而且与 Figure 等美国同行存在严重估值差距。因此,财务结论是:资本充足性谨慎正面,透明度中性偏负,收入质量尚未解决。核心尽调要求不是再看一次愿景演示,而是一张按日期串起订单、已交付单元和已确认收入的财务桥,并按业务线披露利润率和现金消耗。[CI026, CI030, CI031, CI032, CI033, CI034]

4.7 图表

Chapter 05

05产品与技术

5.1 以客户工作流定义产品

Galbot 的产品最好理解为具身劳动自动化,而不是通用人形机器人展示。在客户工作流里,G1 替代的是结构化室内环境中的重复拣取—搬运—放置、扫描—分拣—配送和引导服务任务;在这些场景里,触达灵活性和连续在线比富有表现力的双足行走更重要。在药房,工作流是货架扫描、药品识别、取药和交接;在自主便利零售中,是紧凑 50 平方米门店里的补货、订单拣选、无人收银支持和非营业时间运营;在工厂中,是常规搬运、零部件移动,并最终走向精密装配。因此,这台机器人位于移动操作机器人和人形服务工人之间:双臂、躯干升降和大垂直工作空间,让它能操作为人类设计的货架和柜台;轮足底盘则优先保证稳定性和续航。这个框架重要,因为 Galbot 的公开部署强调的是狭窄但经济上可读的工作,而不是无约束家庭自主。[CE001, CE002, CE008, CE026, CE027, CE030]

FE001: 产品模块流

从客户环境进入 Galbot 具身 AI 模块和运营任务的工作流图。

这张流图抽象的是公开产品叙事,不是厂商发布的系统图;它反映官方描述和部署报道暗示的工作流角色。

[CE001, CE009, CE012, CE013]

5.2 硬件平台与运行架构

Galbot 官方资料为 G1 提供了异常具体的硬件边界。平台标准姿态身高 1730 mm,躯干可升降 650 mm,垂直工作空间延伸至 0–2100 mm;710 mm 手臂和约 190 cm 臂展覆盖标准人体腰部上下的货架和柜台。双臂负载列为 5 kg,足以处理药盘、零食袋、瓶装商品和轻型工业零件,而不是重型制造载荷。动力来自 48V 30Ah 锂电池,宣称最长运行 10 小时,并配有 WiFi、Ethernet、USB 和云端集成用于车队监督。最影响部署经济性的设计选择是轮足移动结构:Galbot 看起来在优化稳定室内导航和更长续航,同时通过躯干升降和长臂几何保留人类空间触达能力。6.25 英寸触摸屏提供本地操作员交互,多模态视觉、触觉和深度感知则支撑硬件之上的具身控制栈。一个规格冲突仍在:官方包引用的机身重量约 92.5 kg,而二级评测有时称 85 kg。[CE002, CE003, CE004, CE005, CE006, CE007]

G1 硬件规格
参数备注对比背景
高度(标准姿态)1730 mm官方产品包和产品页均指向站立高度约 173 cm。人形尺度服务机器人,尺寸适配标准货架和柜台。
躯干升降650 mm躯干大行程升降扩大了高低货架触达范围,不改变底盘占地。室内零售和药房作业里,这比腿部表现力更关键。
臂长710 mm官方产品包已披露。长触达双臂几何补足了稳定轮式底盘的工作半径。
垂直工作空间0–2100 mm官方产品包给出标准范围,并称部分姿态下可触达更高位置。覆盖地面料箱到高位零售货架。
双臂载荷5 kg载荷看起来针对物品搬运调校,不是重型装配。适合 SKU、托盘、瓶装品和轻型零件。
电池48V 30Ah 锂电池电池规格来自官方;循环寿命和热插拔设计未披露。支撑公司声称最长 10 小时续航。
运行时长最长 10 小时公司声称的续航;未披露工作周期假设。对单班室内作业有竞争力。
防护等级IP54只提供基础防尘和防溅水能力。低于严苛工业或临床清洁制度常要求的认证深度。
传感器视觉、触觉、深度模态公开,但传感器供应商和冗余层未披露。足以支撑抓取、跟踪和避障操控。
连接能力WiFi、Ethernet、USB、云集成显示其面向机队管理,也保留本地接口选项。便于接入互联零售和企业网络。
机身重量官方 ~92.5 kg;部分评测 ~85 kg在建模楼面承载或运输前,需要先解决不同来源的重量冲突。影响搬运、移动能耗和安全规划。

各行仅汇总截至运行日期公开披露的规格。若二级来源与官方产品包不一致,先列官方值,并在备注中披露差异。

[CE003, CE004, CE005, CE006, CE007]
FE002: 技术栈示意图

分层展示公开 Galbot 技术栈里的传感器、控制、基础模型,以及开发者 / 车队管理界面。

Galbot 尚未发布标准技术栈图,因此本图根据官方资料包、开发者门户和相互印证的新闻报道重构架构。

[CE005, CE014, CE015, CE016, CE018]

5.3 AI 栈、数据引擎与开发者接口

Galbot 的软件故事围绕垂直化视觉—语言—动作模型展开,而不是单一通用基础模型。GraspVLA 被定位为核心具身抓取模型,基于数十亿次仿真交互训练,并由 DexGraspNet 规模的抓取数据支撑;商业承诺是对未见过的物体和任务实现零样本处理。TrackVLA 把栈延伸到导航和跟随行为:视觉追踪人或物体,接受语音命令,并在目标短暂丢失后重新捕获。GroceryVLA 则把抽象收窄到零售操作,声称可在杂乱门店中处理可变形零食袋、刚性瓶和易碎罐,且无需针对每个 SKU 重新编程。Galbot 把这些模块描述为“脑—小脑—神经控制”架构,把感知、决策和低延迟反馈控制压缩进一条比传统机器人栈更端到端的管线。数据护城河主张建立在超过 100 亿个数据点和 Sim2Real 循环之上,后者高度依赖合成数据生成,据称使用 NVIDIA Isaac Sim,随后用有限真实世界数据微调。公开开发者平台说明确实存在真实集成接口,但公开文档仍比全球领先具身 AI 同行暴露得更少。[CE009, CE010, CE011, CE012, CE013, CE014]

AI/软件栈
组件描述声称能力差异化证据质量
GraspVLA端到端具身抓取基础模型无需额外训练,即可零样本泛化到新物体和新任务把大规模仿真预训练与自有机器人执行闭环结合中高:官方和行业媒体相互印证,但没有公开基准测试套件
TrackVLA导航与目标跟踪模型跟随人或物体,接受语音指令,遮挡后恢复跟踪在杂乱空间里把移动能力和意图跟随接起来中:公司材料有描述,但外部技术细节有限
GroceryVLA零售专用操作模型无需逐品类重编程,即可处理可变形、刚性和易碎物品针对真实门店库存做垂直专精,而不是泛化机器人演示中高:官方描述和部署报道支撑
大脑-小脑-神经控制架构感知-决策-控制一体化栈把多模态输入转成低延迟动作闭环声称比传统模块化机器人栈更端到端中:架构停留在营销层描述,没有系统论文
开发者平台公开开发者门户和手册提供集成和二次开发接口说明 Galbot 想做伙伴可扩展性,而不只是卖封闭设备中:门户存在公开可见,API 深度仍不清楚
Sim2Real 数据引擎合成数据预训练加有限真实世界微调减少人工重标注,加快迁移到新场景若仿真质量足够高,可能形成数据飞轮优势中高:有独立报道,但未经基准测试验证

证据质量衡量每项说法有多少来自一手技术细节,而不是二级报道。目前没有公开基准测试仓库或可复现评估工具链可用于这些模型。

[CE009, CE010, CE012, CE013, CE014, CE016]

5.4 部署成熟度、可靠性与支持信号

公开部署证据显示,Galbot 已走出实验室演示,但尚未发布能证明工厂级可靠性的车队运营台账。最强的量化证据点来自医疗:北京药房部署的媒体报道引用了 10 多个运营站点、24/7 运行模式和 99.5% 药品处理成功率;零售报道则称一台 G1 能自主运营 50 平方米门店,铺开目标扩至 100 多个药房或门店站点。这些是有用的成熟度信号,因为它们意味着公司已反复集成进有货架、SKU 和员工工作流的真实环境。工业成熟度更有前景,但还未被证明。Bosch 和 UAES 的合资公告显示,流程制造和汽车伙伴已认真看待 Galbot;但公开文件仍未发布产线级吞吐、MTBF、恢复时间或服务人员配比。竞争含义是,Galbot 今天在半结构化室内运营中看起来可信,但 99.9%+ 工业准确率的路线图可信度,仍取决于围绕正常运行时间、异常处理和部署支持工具的私下尽调。[CE019, CE020, CE025, CE026, CE027, CE028]

部署场景
垂直场景用例部署阶段已验证指标证据质量
药房货架扫描、药品取放、引导配送已在北京 10+ 家药房运营资料称药品处理成功率 99.5%,7x24 小时运营中高:多家独立报道,但没有官方案例仪表盘
自主零售 / Galbot Store在紧凑空间内补货、拣选、运营门店商业化铺开资料称单台机器人可运营 50 平方米门店,铺开目标 100+ 家中:公司和二级报道支撑,但第三方财务验证有限
即时零售仓连续拣选和库存搬运运营中 / 规模化试点融资公告称已稳定 7x24 小时运营一年以上中:官方新闻稿说法缺少站点级利用率数据
汽车 / 复杂装配常规作业和未来装配自动化试点 / 合资扩张没有公开吞吐量数字;已披露 Bosch 和 UAES 合作中:伙伴背书增强可信度,但量化披露少
电池制造由 CATL 关系牵引的常规工厂作业从试点到早期商业化项目组合层面声称有数千台工业订单中高:官方融资公告加外部报道支撑
医院服务工作流病房支持、药房、导诊系统合作 / 试点具名 Xuanwu Hospital 合作,但没有公开 SLA 指标中:官方公告确认范围,但未确认结果

阶段反映当前最强公开证据,不代表私人合同状态。除药房成功率和广义铺开数量外,量化指标稀少;因此证据质量仍低于成熟工业自动化厂商通常会发布的水平。

[CE008, CE019, CE020, CE026, CE027, CE029]
路线图与里程碑
项目状态目标日期证据风险
GraspVLA 发布已发布2025-01-01Robotics & Automation News 报道,公司技术信息也同步提及目标很高,但公开基准测试透明度仍有限
药房覆盖超过 10+ 家门店推广中2025-12-31Aparobot 及后续推广报道提到 100+ 家目标跨站点扩运营、守合规,可能比试点更难
Bosch BOYIN 工业联盟已签约 / 实施阶段2025-06-01融资报道和合作伙伴材料宣布了合资公司工厂经济性和产线级 KPI 仍未披露
UAES RoboFab 汽车实验室已启动2026-03-01国家背书和融资报道提到该实验室实验室活动尚未证明多站点生产部署
两年内把工厂车间人形机器人推向商业化管理层目标2027-07-01TechNode 和 China Daily 引述公司领导层说法进取目标要靠准确率、安全性和服务可靠性追上宣传

目标日期只是公开里程碑锚点或管理层表态,不是经审计的交付承诺。风险聚焦于已宣布合作 / 启动与可重复生产经济性证据之间的落差。

[CE009, CE019, CE020, CE028, CE029, CE030]
FE003: 各场景部署成熟度

基于已披露运营证据,比较 Galbot 公开部署场景的相对成熟度。

分数是分析师基于公开部署证据数量给出的 1–4 成熟度判断:4 = 有指标的重复运营;3 = 持续部署但指标稀疏;2 = 具名试点或合资公司;1 = 仅概念。

[CE026, CE027, CE029, CE030, CE038]

5.5 差异化、安全、合规与路线图可信度

Galbot 的核心差异化不在某个单点组件,而在整套栈的组合:自有数据、具身基础模型、机器人硬件,以及进入零售、医疗、制造落地场景的通道。与 Peking University、BAAI、Bosch、UAES 的合作强化了一点:Galbot 想搭的是数据和制造飞轮,而不是一次性产品。2025 World Humanoid Robot Games 和药品分拣挑战的第三方验证,也给出一定信号:这套栈能泛化到有基准的任务。不过,安全与合规只被部分去风险。IP54 有用,但只是有限的防尘防水,不等于医疗、工厂或隐私认证的细节。中国 2026 年 3 月人形机器人标准和 2026 年 5 月机器人数字身份 制度会抬高基础合规义务;法律评论也指出,责任、自治和数据处理仍有问题未解。最尖锐的信任缺口是隐私:一篇反向报告明确指出,Galbot 尚未解释药房场景里患者可识别个人身份的健康信息如何得到保护。这个遗漏不推翻产品本身,但也意味着,要进一步打入医疗场景,路线图可信度仍取决于尚未公开的治理和安全披露。[CE021, CE022, CE023, CE024, CE031, CE032]

信任 / 质量 / 合规表
控制 / 认证 / 质量指标状态范围缺口
IP54 防护等级已公开披露机器人外壳可承受轻微粉尘和溅水不能替代详细医疗认证或严苛工厂环境认证
药品处理成功率药房场景引用 99.5%医疗 / 药房拣选流程方法论和样本量未公开披露
中国人形机器人标准2026 年起适用的监管制度国家安全 / 合规基线Galbot 具体符合性文件未公开
机器人数字 ID 注册2026 年 5 月起中国强制要求机队注册和可追溯性运营合规流程未公开描述
隐私与患者数据控制未公开详细说明医疗部署PHI/PII 安全架构仍是重要尽调缺口

本表把已披露控制与缺失披露拆开。公开资料没有隐私和认证细节,表中将其视为缺口,而不推定合规。

[CE006, CE026, CE031, CE032, CE034, CE035]
FE004: 产品成熟度 / 能力图谱

从 Galbot 主要模块和部署环境切入的能力成熟度视图。

评级是截至运行日期、基于公开证据的定性判断。强代表已有实际部署或详细规格支撑;弱代表披露多停留在营销层面。

[CE013, CE018, CE026, CE030, CE038]
Chapter 06

06客户

6.1 客户基座细分与公开足迹

Galbot 的客户版图,与其按经典 SaaS 账户清单理解,不如拆成采购方、使用方和付款方。工业制造里,采购和付款方是 CATL、Bosch 相关实体、BAIC、SAIC、Toyota 提及客户、UAES 等大型企业或战略伙伴;日常使用者是工厂操作员、生产团队和自动化工程师。医疗里,医院或药房运营商买单,药剂师和支持人员使用,直接受益的是患者流程。零售里,Galbot 通过 Galbot Store 和 Galaxy Space Capsule 这类自主便利店形态,部分扮演自己的参考客户,在一些点位既是供应商也是运营者。公开证据显示,所有垂直场景都集中在中国:具名部署、国家支持报道、监管语境和城市级铺开线索都围绕中国展开。这给 Galbot 带来清晰的本土切入口,但也说明,当前客户基座按地域和政策体系看,比垂直清单乍看之下更集中。[CU001, CU002, CU003, CU022, CU024, CU035]

按垂直领域划分的客户分群
垂直领域代表性客户部署状态台量代理指标收入模式
工业制造CATL、BAIC、SAIC、Toyota、Mercedes-Benz、Zeekr、Bosch/UAES 生态试点至早期商业扩张数千台工业订单主张是主要代理指标机器人销售加部署 / 服务,可能由伙伴协助
医疗Xuanwu Hospital、北京药房运营商运营点加旗舰合作10+ 家药房;医院范围公开但未量化部署合同和服务 / 支持收入
零售 / 便利店Galbot Store、Galaxy Space Capsule 网络已运营并扩张2025 年 30+ 个城市;2026 年 20+ 个城市 100+ 台公司自营门店和 / 或托管自动化方案
仓库 / 物流未具名自主仓库客户已运营,但归属披露稀疏引述称已 24/7 运行超过一年;地点数量未披露部署加持续运营 / 支持

分群依据公开部署叙事,而不是已披露收入拆分。台量代理指标采用各垂直领域最强的公开数量,不应解读为按收入加权的份额。

[CU001, CU003, CU015, CU021, CU022]
FU001: 客户部署柱状图

按垂直场景梳理公开识别的部署足迹,并为每个分段采用目前最强的单位数或客户代理指标。

不同柱子代表不同公开代理指标,不是同一个归一化分母。本图意在显示证据密度在哪里,而不是直接比较各垂直场景收入。

[CU003, CU011, CU013, CU016]

6.2 采用轨迹与部署台账

Galbot 的采用轨迹主要看部署数量,而不是已披露收入或分群指标。最重要商业信号是 2025 年 12 月融资稿:公司称来自以 CATL、Toyota、BAIC Group 为首的工业客户的累计订单达数千台。这个说法足以指向真实需求管线,而不是少数试点;但其中有多少是约束性订单、框架协议或分阶段铺开,公开材料没有拆开。零售方面,公司称截至 2025 年底 Galbot Store 已扩展到 30 多个城市,后续报道又指截至 2026 年 3 月,20 多个城市已有 100 多台设备。医疗方面,北京至少 10 家药房在运行,并提到 99.5% 药品处理成功率和 24/7 运行。仓储还提供了另一个耐久性替代指标,官方融资表述称已稳定全天候运行超过一年。合起来看,这些信号显示公司正从展示性安装走向可重复部署模板;但公开采用情况仍需谨慎解读,因为 Galbot 不披露利用率、单机器人经常性收入,也不披露试点转扩展机队的比例。[CU005, CU011, CU012, CU013, CU015, CU024]

采用指标台账
指标数值 / 估计日期置信度缺口
累计工业订单数千台2025-12-16中高具有约束力订单与分阶段框架的混合未公开拆分
零售城市覆盖30+ 个城市2025-12-16未附同日台量
零售单元覆盖20+ 个城市 100+ 台2026-03-02二手报道;未拆分自有点位与第三方点位
北京在运营药房10+2026-03-14中高具体门店清单和复用经济性未披露
药品处理成功率99.5%2026-03-14方法论和样本量未发布
仓库场景连续运营24/7 超过一年2025-12-16地点和停机日志未披露
累计融资额累计 $800M+2026-03-02资本是信心信号,不是直接客户指标
公开留存披露NRR、GRR 或流失均无披露2026-06-14重要客户持久性缺口

台账把直接采用指标与一条明确未披露项放在一起,因为留存数据缺失会显著影响本章。除非来源本身使用“数千”等近似表述,否则不加入估计。

[CU005, CU011, CU012, CU013, CU015, CU018]
FU002: 采用 / 部署漏斗

从宽泛商业主张往下,收敛到更小的一组公开量化部署证据。

这个漏斗衡量公开证据质量,不衡量内部销售漏斗转化。它凸显 Galbot 有很多具名关系,但只有极少部署披露了可独立审计的商业指标。

[CU016, CU023, CU032, CU038]

6.3 具名客户证明与证据质量

具名客户证明,在 Galbot 或高可信融资报道明确把客户标识和实际工作流连起来时最强。CATL 是最清晰的工业锚点,因为材料把它同时描述为领投方 和客户,并把工厂日常作业及大额累计订单同这段关系绑定。Xuanwu Hospital 是最清晰的医疗锚点,因为公司公开把患者病房、药房和院内导引纳入该合作范围。BAIC、SAIC、Toyota 是有分量的客户标识,但证据权重不完全相同;它们主要出现在融资或公司画像报道中,作为具名下单或产业协同客户,而不是深度案例。Mercedes-Benz 和 Zeekr 出现在 TechNode 关于本地工厂轮式机器人的报道里,但缺少详细运营记录。Bosch 和 UAES 更适合当作伙伴-客户混合渠道:合资和合作验证了市场需求与工厂入口,但公开材料还不能证明这些主体已经形成常态化机队采购。零售证据比较特殊,因为 Galbot 自营门店既是部署证明,也是部分自营渠道;这能改善运营反馈回路,但用于集中度分析时,不如独立客户标识有力。[CU004, CU006, CU007, CU008, CU009, CU010]

具名客户部署
客户垂直领域部署类型规模成果指标证据质量日期
CATL电池制造面向生产的常规工厂作业战略客户;属于数千台工业订单池的一部分无公开现场 KPI;最强证据是投资人与客户身份重合关系存在的证据高;运营细节中等2025-12-16
Xuanwu Hospital医疗覆盖病房、药房和导诊系统的医院合作具名旗舰机构工作流范围已确认;未发布 SLA 看板具名证据高;量化结果中等2025-12-16
北京海淀药房医疗 / 药房在运营药房机器人北京 10+ 个运营点药品处理成功率 99.5%;24/7 运行中高:独立媒体加多次引用2026-03-14
Bosch / BOYIN 联盟工业制造合资公司牵头扩展工厂自动化平台渠道,而非已确认机队数量无公开吞吐量 KPI中:合作伙伴信号强,采购细节透明度低2025-07-03
UAES / RoboFab汽车制造面向具身 AI 制造的联合实验室实验室启动 / 扩张载体无公开机队或生产率 KPI中:具体项目明确,但运营深度仍早期2026-03-02
BAIC Group汽车制造具名工业订单客户纳入数千台订单叙述未披露现场 KPI中:仅在融资 / 画像报道中反复出现2025-12-16
SAIC Motor汽车制造具名工业订单或协同客户2026 年报道中提到未披露现场 KPI中:仅二手报道2026-03-02
Toyota汽车制造具名工业订单客户纳入官方订单名单未披露现场 KPI中高:官方点名,但无案例研究2025-12-16
Mercedes-Benz汽车制造工厂机器人部署提到本地工厂使用无公开量化结果中低:单一二手报道2025-06-25
Zeekr汽车制造工厂机器人部署提到本地工厂使用无公开量化结果中低:单一二手报道2025-06-25
Galbot Store / Galaxy Space Capsule 门店体验零售 / 便利店公司自营自主门店网络2025 年覆盖 30+ 个城市;2026 年在 20+ 个城市部署 100+ 台门店覆盖和推广数量已披露中:运营证据真实,但部分来自自有客户场景2026-03-02

本清单汇总截至运行日公开具名的部署或伙伴牵引的运营场景。清单并不穷尽,因为 Galbot 没有发布标准客户台账,部分客户标识只出现在融资或画像报道中,没有独立案例研究。

[CU004, CU005, CU006, CU007, CU008, CU009]
具名客户证明表
客户细分领域部署 / 用例生产 / 试点结果限制
CATL工业制造常规工厂作业和战略订单计划面向生产的早期商业化属于数千台订单主张的一部分无公开工厂级 KPI 或续约数据
Xuanwu Hospital医疗病房、药房、导诊合作试点至早期生产具名旗舰医疗部署无公开 SLA 或扩张细节
北京药房运营商医疗药品取放和药房自动化运营中的生产站点引述称处理成功率 99.5%;24/7 运行方法论未披露
Galbot Store / Galaxy Space Capsule 门店体验零售自主便利零售网络生产化推广先覆盖 30+ 个城市,后在 20+ 个城市部署 100+ 台部分自营,独立性较弱
Bosch / UAES 渠道工业制造合资公司牵头的工厂扩张和汽车实验室试点 / 渠道建设验证需求和进入工厂车间的通道尚未证明常态化机队采购

面向验证器的清单表用规范化结构收纳最强的具名客户证据,补充而不是替代上方更广的用户要求具名部署表。

[CU004, CU010, CU011, CU013, CU016, CU033]
FU003: 客户证据矩阵

矩阵展示 Galbot 在当前垂直场景中,哪里有具名客户、规模信号和量化结果。

评级为定性判断,只反映截至报告生成日可见的公开证据。“强” 指公开记录直接点名且量化;“中等” 指有一定支撑,但不足以完成完整商业验证。

[CU023, CU032, CU037]
FU004: 客户旅程图

从战略关系到实际部署,再到潜在机群扩张的高层路径。

这是根据公开部署叙事重构的概念性旅程图,并非供应商发布的销售流程图。

[CU022, CU028, CU029]

6.4 留存代理指标、扩张路径与渠道动态

Galbot 不公布 NRR、GRR、客户留存、流失率或合同期限数据,所以客户耐久性只能从结构性信号推断。最正面的代理指标是运营连续性:官方材料提到仓储场景 24/7 使用超过一年,药房部署也在继续,这意味着至少有部分客户选择把机器人留在工作流里,而不是试点后撤掉。第二个代理指标是战略绑定。CATL 同时是投资方和客户,很可能加深锁定,因为这段关系横跨资本、信用背书和工厂使用;但同样的紧密度也引入关联方风险。扩张路径看起来通过三类渠道推进:面向标杆工业和医疗账户的企业直销,通过 Bosch 和 UAES 进入制造业的伙伴渠道,以及 Galbot 自营零售形态——先验证自身经济性、收集数据,再把模板向外销售。药房从 10 多个点位走向 100 多个点位的铺开目标,也暗示如果单个工作流验证成立,可以复制到更多地点,就能形成先落地再扩张的打法。缺口仍是商业质量披露:公开信息没有说明续约时间、机队追加销售率、软件绑定率,也没有说明已安装基座中有多少是付费生产环境,多少是补贴式战略铺开。[CU018, CU019, CU026, CU027, CU028, CU029]

客户集中度与风险
因素评估证据
CATL 关联方集中度官方与独立报道多次出现其既是领投方、又是核心工业客户的关系
地理集中度截至运行日,所有主要公开部署和具名客户标识都以中国为中心
垂直领域集中度中高尽管有医疗和零售多元化,工业制造似乎仍是最大订单池
留存披露风险无公开 NRR、GRR、流失或续约数据
证据质量风险多个客户标识只出现在融资报道中,而非详细案例研究
需求成熟度风险中高独立负面报道称,全行业真实买家需求和用例仍有限

评估是基于本章最强公开证据作出的分析师判断。风险等级只表示方向;一旦拿到集中度和续约记录,应以数据室指标替换。

[CU020, CU024, CU030, CU031, CU038]

6.5 集中度风险与反向信号

客户故事有吸引力,但并未充分去风险。CATL 同时是 Galbot 最具战略性的投资关系,也是最清晰的工业客户锚点;这带来集中度和治理问题,而私营公司的公开记录还无法回答。公开部署也高度中国中心化,使 Galbot 暴露在同一个监管环境、人才生态和人形机器人系统早期采用市场中。独立反向报道让警惕更强:TechXplore 认为人形机器人供给可能跑在真实买方需求之前,因为可用生产场景仍有限;CNBC 也把该赛道描述为投资人热、商业化未成熟。这些批评贴合 Galbot 的证据形态:公开客户标识和铺开数量是真实的,但详细机队经济性、续约情况、第三方验证的生产率结果仍稀少。多个垂直场景和伙伴渠道确实降低了一些单一市场风险,但数千台订单说法,相比 Galbot 融资轮次和制造叙事隐含的规模雄心,仍处早期。简言之,采用动能真实存在,但集中度与商业化质量尚未达到后期工业平台投资人想看到的证明强度。[CU017, CU020, CU021, CU025, CU030, CU031]

Chapter 07

07风险

7.1 风险概览与排序

Galbot 的风险画像不是被某个致命缺陷主导。公司融资可信、部署可见,也有中国本土市场顺风;但这些正面因素可能掩盖一个事实:人形机器人经济性要变得可持续,许多依赖项必须同时跑通。最严重的风险出现在政策、商业化和集中度交叉处。中国的标准和 数字身份制度最终可能帮到可信供应商,但短期内会形成具体的合规门槛和召回义务。与此同时,公开报道仍显示,赢得买方比造出机器人更难;因此,即便技术演示 表现好,规模假设也可能落空。再叠加 CATL 集中、高硬件资本强度和未披露收入指标,下行情形就不是单点爆雷,而是多项风险累积。[CR001, CR002, CR014, CR020, CR026, CR027]

缓释措施与终止标准表
风险可监测指标触发因素 / 阈值重要性行动含义
监管合规拖累数字 ID 注册和标准认证的公开证据商业部署在 2026-2027 年扩张时,仍没有清晰合规证明说明政策风险在卡住规模化,而不是推动规模化视为重大尽调阻断点
CATL 集中度可见部署或收入中绑定 CATL 的占比CATL 实质性减少订单、试点范围或投资支持会同时打击收入证明和融资信号大幅降低估值容忍度
买方需求疲弱旗舰参考之外具名复购客户机器人仍停留在展示部署,没有广泛续约或扩张说明需求没有复利式增长按试点占比高的硬件公司承销,而不是可规模化平台
安全 / 网络事故重大现场故障、召回或安全入侵新数字 ID 制度下发生一次严重事故可能同时触发责任、召回成本和需求犹豫暂停投资,直到根因和应对清楚
单元经济性不及预期机器人无法稳定替代目标班次人力的证据支持成本或正常运行时间短板侵蚀客户 ROI会同时削弱需求和利润率假设转入熊市情景框架
政治 / 出口冲击关键算力或出口渠道受限新的出口管制摩擦影响性能路线图会拖慢模型迭代,并压缩国际化选择权降低对长期倍数扩张的信心

这些触发项都写成可观察指标,让本章能直接服务于投资、等待或放弃的决定,而不是止步于泛泛提醒。

[CR008, CR020, CR031, CR032, CR038, CR039]
FR001: 风险热力图

该序数矩阵按可能性、影响、缓释成熟度和剩余暴露给 Galbot 主要风险类别排序。

评级是截至 2026-06-14 对引用证据综合后的序数型投资判断,不是预测概率。

[CR001, CR003, CR013, CR014, CR016, CR020]
FR004: 风险类别条形图

集中度和监管叠加尚未验证的规模经济时,严重度最高。

条形值是投委会式的 1-5 序数严重度评分,不是概率。

[CR010, CR020, CR026, CR029, CR040]

7.2 监管、法律与安全风险

Galbot 的监管图景格外重要,因为中国政府不只是旁观人形机器人,而是在围绕它们建立可执行框架。2026 年 3 月的国家标准体系和 2026 年 5 月的数字身份制度,让人形机器人更接近受监管的工业产品品类;这利好长期市场发展,但会让准备不足的供应商付出高成本。法律风险也不止合规清单。Hill Dickinson 的分析有说服力,因为它把责任、隐私和问责视为未解问题,即便完全自治还未到来。若机器人伤到工人、误识别人,或在药房/医院误处理敏感数据,责任可能横跨制造商、运营方和软件栈。也就是说,一次重大事故可能同时触发商业观望、监管审查和直接成本。[CR001, CR002, CR003, CR004, CR005, CR006]

监管 / 法律风险登记表
司法辖区 / 议题当前状态要求 / 暴露Galbot 合规姿态缺口严重性
中国国家人形机器人标准体系2026 年 3 月宣布框架制造商必须对齐安全、伦理、测试和互操作预期Galbot 受益于本土对齐,但仍要落地实施未披露公开认证材料包或合规路线图
中国机器人数字 ID 制度2026 年 5 月起运行注册成为市场准入和可追溯要求Galbot 在中国运营,最终应为已部署单元注册暂无单元级注册或召回流程的公开证明
缺陷召回与转售限制嵌入数字 ID 制度缺陷单元可能需要召回;翻新或转售受到限制抬高硬件缺陷和服务失误成本未公开披露缺陷准备金或召回准备情况
事故后的责任分配法律分析仍未定论损害可能引发针对制造商、运营方和软件提供商的索赔Galbot 混合 B2B 环境让运营方与制造方责任边界更复杂未披露公开赔偿或保险框架中高
隐私 / 生物识别处理人形机器人可能处理工作场所和客户数据跨境隐私与生物识别规则并不统一医疗和零售部署让数据最小化很重要未披露面向医疗部署的公开隐私架构中高
地缘政治技术管制芯片和市场准入仍具政治敏感性限制可能拖慢先进算力获取或出口增长Galbot 提到过供应链多元化,但仍有暴露未公开模型训练层面的多供应商缓释细节

登记表聚焦政策和法律约束;即便机器人本身看起来技术上可行,这些约束也可能叫停部署。

[CR001, CR002, CR003, CR004, CR005, CR008]
FR002: 风险传导图

主要下行路径是:监管收紧、需求集中,进而拖慢采用、削弱单位经济,并推高融资压力。

[CR002, CR013, CR014, CR026, CR030, CR031]

7.3 运营可靠性与产品化风险

运营可靠性仍是从亮眼原型叙事到韧性业务之间最大的桥。公开来源支持人形机器人系统正在快速变好,但也显示,买方要看到可重复节省,前面还有很多环节必须成功。工厂部署需要极高准确率和 正常运行时间;具身 AI 的错误不会像仪表盘指标那样悄悄变差,而可能外溢成物理事故。Deloitte 对物理 AI 的警示在这一类风险中比在纯软件里更重要,因为幻觉和感知错误会驱动执行器在人周围移动。电池完整性、触觉传感和网络加固还会叠加更多层。TechXplore 和 Associated Press 的报道同样有价值,因为它们把当前商业瓶颈框定为需求和信任,而不是原始生产速度;这正是那种会在大量资本投入后才显形的风险。[CR013, CR014, CR015, CR016, CR017, CR018]

运营 / 质量 / 安全风险登记表
失效模式重要性可能性影响当前缓释措施残余暴露
可靠性低于工厂级门槛若准确率或正常运行时间达不到生产容忍度,工业 ROI 就会失效试点部署和全栈优化公开正常运行时间数据仍缺失
买方需求落后于硬件产出机器人造得比卖出或续约更快时,规模经济跑不出来标杆客户与国资背书带来的可见度需求能否大规模形成仍未证实
物理 AI 幻觉或感知错误真实环境里,软件错误会变成安全事故中高仿真、测试与受限任务设计意外边界场景仍难消除
联网机队遭网络入侵远程入侵可能同时造成数据泄露和物理安全事故企业级控制与托管环境未见公开安全保证报告
电池热失控或充电问题人群附近运行的人形机器人会带来电池起火和服务风险电池设计与标准锂电安全实践未见公开事故或拨备披露
触觉感知与灵巧性瓶颈机器人在拉动利用率的精细人类任务上仍可能失手中高任务专门化与全栈软件迭代通用化叙事可能跑在现场现实前面

这些运营行聚焦会直接拖累正常运行时间、安全和真实客户价值的失效模式,而不是泛泛的制造公司风险。

[CR006, CR007, CR013, CR014, CR015, CR016]

7.4 伙伴依赖与财务模型风险

公司的最强外部证明点也同时是集中度风险。CATL 给 Galbot 带来有分量的工业背书和融资信号,但也把需求可信度与投资人信心集中到一段关系上。Bosch 相关合作、国资背景资本、NVIDIA 相关工具链,让公司看起来战略连接度高;但一旦条款变化、政治环境转向或平台入口收紧,每条连接也会压缩自由度。财务上,公司仍难以清晰判断投资价值,因为公开证据给出了估值和融资数字,却没有可比的收入、现金消耗或支持经济性披露。这个组合形成一种具体下行情形:如果买方需求比标题式部署集合更窄,Galbot 仍可能显得很突出,却需要按不确定条款继续融资。因此,Galbot $3 billion 估值与 Figure 更高得多的美国同行估值标记之间的差距,应部分理解为风险折价,而不只是可选上行空间。[CR020, CR021, CR022, CR023, CR024, CR025]

合作伙伴 / 依赖风险清单
依赖项合作伙伴 / 供应商依赖性质锁定程度可替代性风险等级
锚定客户 + 投资人集中CATL需求证明、资本信号和产业验证部分押在同一个对手方身上中低
制造 / 合资渠道Bosch 关联合资公司与生态伙伴合作伙伴可影响分销、经济性和路线图对齐中高中高
国资与银行National AI Fund、Bank of China、Sinopec、CITIC、SAIC 关联资本政策通道和融资厚度部分取决于政治对齐中低中高
算力与仿真栈NVIDIA Jetson Thor / Isaac 配套工具与云算力训练和开发流程可能依赖集中度较高的生态中高中高
中国机器人供应链国内执行器、传感器与集成生态规模化取决于供给持续可得,以及跨境零部件通道畅通
医疗与零售落地伙伴医院、药房和商业场所通用性证明取决于伙伴是否愿意把试点扩到生产部署

这张图按单一外部主体或平台同时削弱收入信心和未来融资的直接程度,对依赖项排序。

[CR020, CR021, CR022, CR023, CR024, CR025]
人员 / 执行风险清单
要素描述严重性缓释措施剩余风险
创始人集中He Wang 同时承担创始人、CEO 和资深学者角色技术信誉和公众形象强注意力分散会拖慢运营节奏
全栈跨度模型、硬件、数据和商业化并行推进一体化架构可减少跨供应商摩擦并行下注太多会削弱执行聚焦
商业证明与技术证明已有参考部署,但规模化复购不够可见工业和医疗客户标识带来可信度可复制性仍不如展示成功那样经受验证
财务不透明收入、烧钱速度和单元经济性仍未披露大额融资争取了时间经济性不透明会削弱下一轮谈判筹码
与政策绑定的增长路径国家支持可能加速国内采用中高国内生态优势确实存在政策依赖会让海外扩张或纯商业扩张更复杂

这些执行项单独拎出三类风险:领导层集中、披露缺口,以及把试点可见度转成可复制规模的难度。

[CR010, CR011, CR026, CR027, CR028, CR033]
FR003: 依赖关系图

Galbot 最强的依赖落在锚定客户、资本方、政策体系和算力平台的交叉处。

[CR020, CR021, CR022, CR023, CR024, CR039]

7.5 缓释因素、监控重点与尽调问题

Galbot 并非没有防线。全栈架构可以减少产品最战略部分对外部供应商的依赖;国资背景投资人加上工业、零售、医疗场景的参考部署,也比许多更早期人形机器人 初创公司拥有更强地基。监管框架也有有利的双刃剑一面:一旦清晰标准和数字身份工作流被内化,资本更充足的供应商可能受益于小竞争对手无法跨过的门槛。中国之外,治理预期也在变得更正式:NIST 把可信 AI 定义为全组织风险管理纪律,而不是狭义模型调优。但这些缓释因素无法抹掉核心尽调问题。投资人仍需要证明:合规工作流已经可运行,CATL 集中度没有过高,正常运行时间和服务成本能支撑替代人工的叙事,且一次严重现场事故不会演变成召回和融资问题。因此,正确姿态是边跟踪边建立信念,而不是一概怀疑。[CR033, CR034, CR035, CR036, CR037, CR038]

7.6 图表

Chapter 08

08估值

8.1 融资语境与入场纪律

Galbot 的正确起点是当前融资标记,而不是常规 DCF 测算。公开证据给出强标题:2026 年 3 月以约 $3 billion 估值融资超过 $300 million;更早融资似乎把累计资本推到 $1.15 billion 以上。这足以把 Galbot 视为中国资本最充足的人形机器人公司之一,但不足以说明当前价格明显公允。公开来源仍未披露审计收入、毛利率、现金消耗率,或决定标题式投后估值能否转化为有吸引力普通股入场机会的详细资本结构。这也是为什么入场纪律比品类热度更重要。新投资人应假设,结构、集中度和商业化时点至少和市场规模叙事同等重要。[CV001, CV002, CV003, CV011, CV015, CV030]

推荐摘要表
维度评估决策含义
推荐继续研究证据有吸引力,但以当前价格锚点直接买入,信息仍过于不透明。
信心判断方向比精确价值区间更清楚,因为关键私营公司指标仍未披露。
风险评级政策、集中度、商业化和披露风险都仍在场。
估值立场偏高当前估值从战略角度说得通,但披露的运营证据还撑不住。
目标回报 / 持有需要 4-6 年内 >3x以 $3B 价格进入,需要异常强的执行和条款纪律才能拿到这类回报。
最可能的近期路径再一轮私募融资或结构化 Pre-IPO 融资IPO 就绪仍需要经审计的经济性和更广泛商业证明。

该建议明确对价格敏感,反映战略潜力与当前已披露运营证明之间的差距。

[CV001, CV011, CV029, CV030, CV031, CV035]

8.2 投资论点:Galbot 为什么仍值得关注

Galbot 的乐观论点很有分量。中国正在成为人形机器人制造和出货规模中心;能把软件、硬件和客户入口拼在一起的公司,会自然获得本土优势。Galbot 自身定位与这个机会一致。公司声称拥有全栈具身 AI 架构、大规模专有数据资产和多层模型,而不是只有一台演示机器人。工业、零售、医疗场景的公开部署证据也显示,Galbot 已越过纯原型阶段。再叠加国资背景投资人、高知名度创始人和 CATL 相关工业验证,公司有理由主张自己正在搭建中国企业采用人形机器人的先发通道。若这些要素在未来两到三年转化为可衡量的重复收入,当前估值最终可能比今天看起来更站得住。[CV003, CV004, CV005, CV006, CV007, CV008]

投资论点 / 反论点表
支柱多头情景空头情景需要解决的问题
市场地位中国的出货领先和制造深度可让 Galbot 比许多海外同行更快复合增长。国内市场拥挤,加上中国资产倍数更低,即使有规模也可能封住上行空间。需要证明在优先垂直领域份额可持续。
产品护城河全栈模型、数据和硬件可形成一体化学习闭环。VLA 收敛可能比管理层预期更快压缩差异化。需要外部证据证明数据和模型优势能转化为更好的现场结果。
商业证明CATL 等部署表明 Galbot 已不只是原型。少数参考客户标识仍可能掩盖集中度和复购疲弱。需要复购订单和多客户扩张证据。
资本基础国资背景投资人提供耐久资本和政策通道。优先权和集中度不明,可能让后进投资人保护不足。需要股权结构、条款和治理细节。
团队质量He Wang 的技术履历支撑具身 AI 叙事。商业化铺开后,创始人集中会抬高执行负荷。需要组织纵深和运营节奏证据。
监管环境标准长期可抬高弱势竞争者的门槛。合规、召回和隐私义务会先拖慢价值兑现。需要合规就绪、医疗和隐私控制的实操证据。

这张表把每个投资论点支柱放到对应反论点下检验;投资人若要激进承销当前价格,必须先解决这些问题。

[CV003, CV004, CV006, CV007, CV009, CV014]
FV001: 建议逻辑

当前估值下,产品和市场潜力被集中度与披露缺口抵消,因此建议仍偏谨慎。

该流程把承销链条压缩成最可能影响投委会决策的少数变量。

[CV004, CV006, CV011, CV016, CV018, CV029]
FV004: 投资 KPI

KPI 面板显示,Galbot 具备战略吸引力,但按当前估值还达不到明确买入门槛。

[CV001, CV002, CV008, CV010, CV011, CV029]

8.3 反方论点:为什么当前价格仍可能过高

反方论点的重点不是人形机器人是否重要,而是投资人是否被要求过早为一个仍不透明的故事买单。Galbot 的 $3 billion 估值没有公开收入或单位经济性披露支撑。正如 TechXplore 报道强调,需求形成仍是品类真实风险;CATL 附近的伙伴集中也意味着,一个耀眼证明点同时是单点脆弱性。合规、责任、网络安全和隐私问题也不抽象;收紧的标准和数字身份系统最终可能帮助强供应商,但首先会提高证明准备度的成本。竞争强度进一步削弱纯溢价论点。Unitree 的定价、AgiBot 的存在、XPENG 的机器人野心,以及 Physical Intelligence 等软件优先平台,都意味着战略稀缺性可能比私募估值标记暗示的更快收窄。以今天的入场点看,这足以让建议保持谨慎。[CV010, CV011, CV012, CV015, CV016, CV017]

论点破裂与终止触发表
项目描述紧迫性未解决是否导致论点破裂
经审计收入证明提供经审计或董事会级别的收入、毛利率和烧钱披露。立即是;没有经济性,价格无法干净承销。
CATL 集中度披露合同条款、期限和依赖组合。立即是;如果单一对手方实质上同时锚定收入和融资信心。
实际交付时间表按主要部署展示实际交付与承诺交付的时间差。是;如果出货相对商业化叙事明显滑坡。
股权结构与优先权披露清算顺位、参与权和优先级。是;如果结构在标称估值下明显压低新资金顺位。
合规状态展示数字 ID、隐私和医疗控制就绪度。是;如果监管可能中断关键部署。

这些触发项围绕会直接改变投资建议的问题展开,而不是只增加泛泛提醒。

[CV010, CV018, CV029, CV030, CV037, CV038]

8.4 可比组与情景区间

Galbot 的有用估值框架必须是混合型。一端,Figure AI 官方 $39 billion Series C 显示,全球资本市场仍会给被视为品类领导者的公司很高定价。另一端,中国同行和上市公司可比标的显示,定价压力、市场折价和披露差异会迅速压缩这种乐观。因此,情景框架比单点估计更重要。乐观情形假设 Galbot 成为清晰的中国本土工业领导者,收入规模真实、战略可选性大幅更丰富。基准情形假设公司取得实质进展,但仍因集中度、披露和政策风险承受折价。悲观情形假设商业化滑坡,或集中度与监管实质削弱未来融资杠杆。区间很宽,但宽度符合现实:今天的公开证据对方向的支持强于对精度的支持。[CV013, CV014, CV025, CV026, CV027, CV028]

牛 / 基础 / 熊情景表
情景概率关键假设隐含 5 年价值驱动因素估值区间
25%中国仍是人形机器人商业化中心,Galbot 赢得工业领域领导地位,收入到 2028 年至少达到数亿美元。经营杠杆叠加本土品类龙头的战略溢价。$25B-$35B
基础50%Galbot 在两到三个垂直领域放量,但披露只逐步改善,市场仍会折价处理集中度和政策风险。收入可见度稳步提升,治理证明改善但仍不完美。$10B-$15B
25%商品化、合规拖累或 CATL 收缩阻止广泛规模化,并迫使融资条款更苛刻。下行保护靠资产和战略选择权,而不是爆发式增长。$1B-$1.5B

这些区间是讨论区间,不是管理层指引;锚点是里程碑推进,而不是单一收入倍数。

[CV012, CV026, CV027, CV028, CV031, CV037]
可比估值表
可比公司类型阶段估值 ($B)收入模式关键差异化估值倍数背景
Galbot私募轮增长 / Pre-IPO 叙事3人形机器人硬件 + 具身 AI 部署中国全栈工业聚焦,背后有国资资本标称私募轮估值,未公开收入披露
Figure AI私募轮Series C / 品类龙头39通用人形机器人平台同业中已披露的最高私募估值官方 2025 年 Series C 轮投后估值
AgiBot私营公司估算私募后期 / 规模化4中国人形机器人部署国内出货可见度强市场报道中点估算,并非官方价格
Unitree公私混合市场标尺商业产品规模机器人硬件销售中国市场公开价格点激进可作为定价锚点,但不是已披露私募估值
XPENG上市可比公司上市 EV / 机器人选择权整车销售 + 机器人选择权披露充分,具备公开市场流动性使用基于申报文件的上市公司背景,而不是直接套用估值
Boston Dynamics / Hyundai战略型既有玩家企业支持的商业化对手工业机器人与战略部署既有玩家的制造和商业化深度战略可比,不适合直接转移倍数
Physical Intelligence基础模型可比公司私营 AI 平台通用机器人模型平台显示价值可能流向软件优先的控制层提供叙事和融资背景,而不是干净倍数

这张表混合了已披露私募估值锚点、上市公司和战略可比对象,因为 Galbot 运营披露不足,无法机械套用单一倍数法。

[CV001, CV013, CV021, CV022, CV023, CV024]
FV002: 可比公司定位

已披露的私人市场估值锚显示,Galbot 仍明显低于美国头部同行;同时也凸显,这些估值之下公开运营披露很少。

条形值单位为百万美元,不包括缺少直接可比私人估值锚的上市公司可比对象。

[CV001, CV013, CV014, CV033]
FV003: 估值情景区间

只有商业化里程碑和财务披露较公开基线显著改善,Galbot 当前价格才有吸引力。

情景区间是以百万美元计的投委会讨论区间,基于里程碑假设,而不是单一收入倍数。

[CV026, CV027, CV028, CV029]

8.5 建议、退出逻辑与最终尽调

本章结论是 research-more。这不是否定 Galbot 的战略位置,而是判断当前公开记录仍留下太多未解问题,无法把 $3 billion 标记称作有吸引力。公司确有优势,包括资本深度、可信的本土市场位置和可见部署;但缺失项恰好是入场质量最关键的部分:审计经济性、资本结构条款、交易对手集中度、出货真实性数据集和详细合规姿态。合理持有期可能是四到六年,因为商业化成熟度和 IPO 准备度 大概率落后于融资故事。建立信念的最佳路径不是更多叙事,而是更窄、更硬的证据。如果审计财务、重复客户扩张和更干净的集中度调整后单位经济性 出现,估值立场可能从偏贵走向公允。在那之前,最终尽调应承担主要工作。[CV029, CV030, CV031, CV036, CV037, CV038]

最终尽调问题表
主题缺失证据重要性负责人 / 尽调路径
经审计收入与单元 P&L季度收入、毛利率、支持成本和现金消耗估值纪律取决于证明业务本身,而不只是证明品类。与管理层和审计师开展财务尽调。
CATL 合同结构期限、定价、排他性和终止权集中度会放大上行,也会扭曲下行。审阅已签协议的商业和法律条款。
交付事实集各站点实际出货量与已宣布部署对比这条投资逻辑需要真实规模,而不只是高曝光试点。运营尽调加客户背调电话。
毛利结构硬件毛利与软件或服务贡献对比决定规模扩大是在抬升价值,还是只是加重支持负担。财务和产品尽调。
员工数与烧钱速度按职能划分的人头数和月度现金消耗用来判断跑道和未来稀释压力。HR 和 CFO 尽调。
知识产权和隐私状态专利图谱、FTO 意见、医疗隐私控制如果基础薄弱,两项都会带来不易察觉的下行风险。法务和安全尽调。

要把一轮战略上有吸引力的私人融资,变成可以完整承销的投资决策,上述材料是最低配置。

[CV011, CV015, CV018, CV019, CV030, CV038]

8.6 图表

附录 A: 方法论与来源覆盖

本报告仅基于截至 2026-07-06 已审阅的公开来源,包括公司官方页面、大学和公司简介材料、独立新闻媒体、分析师市场评论,以及监管或法律来源。报告未使用管理层访谈、客户访谈、保密数据室或未公布财务报表。

由于 Galaxy Bot 是私有公司且财务不透明,本报告大量依赖融资事件、合作伙伴公告、部署案例和市场结构证据做交叉验证。该方法有助于战略尽调,但用于承销内在价值时,明显弱于经审计收入和同期群数据。

免责声明

本报告仅基于公开可得信息,不构成投资建议。Galaxy Bot / Galbot 未审阅或背书本报告。估算和判断反映截至 2026-07-06 可获得的证据;新信息出现后可能变化。

证据索引

结论
编号陈述可信度来源
CO001 Galaxy Bot’s current verified official web presence is galbot.com, where the company brands itself as Galbot. SO001
CO002 Galbot’s official description presents the company as an embodied-AI and general-purpose robotics developer serving multiple industries. SO001, SO002
CO003 Public company-profile evidence places Galaxy Bot’s headquarters in Haidian District, Beijing, China. SO009
CO004 The company was established in May 2023, and Baidu’s profile gives a specific establishment date of May 19, 2023. SO009
CO005 Yao Tengzhou is publicly identified as Galaxy Bot’s legal representative and co-founder. SO009, SO010
CO006 The company completed shareholding reform in late 2025 and changed its name from Beijing Galbot Co., Ltd. to Beijing Galaxy General Robot Joint Stock Co., Ltd. SO009
CO007 Official Galbot materials state that the company operates R&D centers in Beijing, Shenzhen, Suzhou, and Hong Kong. SO003
CO008 Official Galbot materials state that the company has joint laboratories or research centers with Peking University, Xuanwu Hospital, and Beijing Zhongguancun College. SO003
CO009 Galbot’s official site frames commercial retail usage as precision picking, delivery, inventory management, and restocking. SO003, SO001
CO010 He Wang is a tenure-track assistant professor at Peking University’s Center on Frontiers of Computing Studies. SO004
CO011 Peking University says He Wang received his PhD from Stanford University in 2021 under Leonidas Guibas. SO004
CO012 Peking University says He Wang is also the director of the PKU-Galbot joint lab of embodied AI. SO004
CO013 Public founder biographies describe Yao Tengzhou as a Beihang Robotics Institute graduate who previously worked at ABB’s Shanghai robot R&D center. SO010
CO014 Crunchbase reported that Galaxy Bot raised $153 million in June 2025 in a round led by CATL and was valued at $1 billion. SO005, SO013
CO015 The June 2025 financing was widely described as RMB 1.1 billion, or roughly $150 million to $153 million, and independent robotics outlets said cumulative funding had reached roughly $330 million to $335 million. SO006, SO007, SO008, SO013
CO016 Independent coverage named Puquan Capital, China Development Bank-linked funds, the Beijing Robot Industry Fund, and Qiming Venture Partners among the investors around the June 2025 round. SO006, SO008, SO013
CO017 OFweek described Galbot’s cumulative funding after the June 2025 round as more than RMB 2.4 billion within two years of founding. SO006
CO018 Bosch-linked partner coverage says Boyuan Capital, Bosch China, and Galbot announced a joint venture and strategic MOU focused on industrial manufacturing applications on June 17, 2025. SO024, SO008, SO013
CO019 The Bosch-linked JV was positioned to commercialize embodied-intelligence robots for high-precision manufacturing and global markets. SO024, SO008
CO020 In June 2026, CATL and Galbot announced a strategic cooperation agreement, and independent outlets reported that the Galbot S1 had entered CATL smart production lines. SO011, SO012
CO021 Independent coverage described the Galbot S1 as having a 50-kilogram dual-arm payload, vision-based centimeter-level positioning, and omnidirectional obstacle avoidance. SO011, SO012
CO022 Independent CATL-partnership coverage said the S1 could operate for about eight hours on CATL-powered batteries. SO011, SO012
CO023 The Robot Report described the G1 as a wheeled dual-arm mobile manipulator built to automate inventory, replenishment, delivery, and packaging. SO013, SO008
CO024 The Robot Report said Galbot claimed the G1 could handle about 5,000 different types of goods. SO013
CO025 The Robot Report said nearly 10 Beijing stores had deployed the G1 in 2025 and that the company planned to expand to 100 stores nationwide within the year. SO013, SO007
CO026 Aparobot described the G1 as approximately 173 centimeters tall, 85 kilograms in weight, with a 190-centimeter arm span, 5-kilogram payload, and up to 10 hours of runtime. SO022
CO027 GraspVLA is a public Galbot-linked research program built around a billion-frame synthetic robotic grasping dataset called SynGrasp-1B. SO019, SO013
CO028 TrackVLA is a public Galbot-linked research program for embodied visual tracking trained on a 1.7 million-sample benchmark. SO020
CO029 NVIDIA documented Galbot’s DexGraspNet as a 1.32 million-grasp dataset spanning 5,355 objects and more than 133 categories. SO018
CO030 MERICS says China’s humanoid robots still lack precision and dexterity and remain far from fully autonomous operation in real commercial environments. SO016
CO031 MERICS says commercial viability for Chinese humanoid robots would require costs to fall by at least half from current levels. SO016
CO032 KrASIA reported that many investors still view embodied-intelligence commercialization as murky and worry the sector could be a bubble. SO015
CO033 The U.S.-China Economic and Security Review Commission wrote that China’s humanoid-robot goals are partly vague and that the feasibility of achieving them on the stated timeline is doubtful. SO017
CO034 In December 2025, Galbot issued a company press release claiming a financing round exceeding $300 million and a $3 billion valuation. SO014
CO035 The Robot Report later repeated Galbot’s claim that total funding had reached about $800 million and valuation about $3 billion after the December 2025 round. SO025, SO014
CO036 Company-originated late-2025 sources said Galbot Store was operating in more than 30 cities and that Galbot had secured orders for thousands of units. SO014, SO025
CO037 Official Galbot materials say the founding team has published more than 100 influential academic papers in embodied AI and related fields. SO003
CO038 Baidu’s company profile lists the business scope as including service-robot manufacturing and sales, software development, and intelligent-robot R&D. SO009
CO039 Baidu’s company profile names Guo Xiaoliang as the current chairman. SO009
CO040 No reviewed public source disclosed Galaxy Bot’s revenue, gross margin, exact headcount, or board-rights structure, leaving commercialization proof materially incomplete. SO005, SO009, SO013, SO015
CM001 Galaxy Bot’s near-term market sits at the overlap of retail automation, service robotics, warehouse automation, and in-store labor substitution rather than the full universe of humanoid robotics. SM004, SM009, SM015, SM016
CM002 China’s total retail sales of consumer goods reached 48.79 trillion yuan in 2024. SM015
CM003 Online retail sales of physical goods reached 13.08 trillion yuan in 2024, or 26.8% of China’s total retail sales of consumer goods. SM015, SM024
CM004 China’s self-checkout retail market is estimated at about $330 million in 2024 and projected to reach about $1.3 billion by 2035. SM016
CM005 The global warehouse robotics market was valued at about $6.51 billion in 2025 and is projected to reach about $25.41 billion by 2034. SM004
CM006 Warehouse robotics demand is being driven by e-commerce activity, workforce shortages, and the need for operational efficiency. SM004
CM007 High initial investment and maintenance cost remain meaningful barriers to warehouse-robotics adoption despite long-run labor savings. SM004
CM008 The global service robotics market is projected to grow from $47.10 billion in 2024 to $98.65 billion by 2029 at a 15.9% CAGR. SM009
CM009 Service robotics adoption is being driven by return-on-investment pressure, labor costs, and increased use of AI, IoT, and automation across industries. SM009
CM010 Service robotics deployment still faces privacy, liability, standardization, and integration constraints. SM009
CM011 China’s 14th Five-Year Plan for the robotics industry expected robot-industry revenue growth above 20% annually through 2025 and a doubling of industrial robot intensity. SM010
CM012 IFR reported that China’s robot density reached 470 robots per 10,000 manufacturing employees in 2023, ranking third globally. SM011
CM013 IFR reported a 2023 global average robot density of 162, with Korea at 1,012 and Singapore at 770 per 10,000 manufacturing employees. SM011
CM014 IFR’s earlier 2022 release showed China at 322 robots per 10,000 manufacturing employees in 2021, indicating rapid acceleration before the 2023 level of 470. SM025, SM011
CM015 Morgan Stanley projects nearly 1 billion humanoids globally by 2050. SM001
CM016 Morgan Stanley expects roughly 90% of humanoids in 2050 to be used for industrial and commercial work rather than households. SM001
CM017 Morgan Stanley expects China to have about 302.3 million humanoid robots in use by 2050. SM001
CM018 Morgan Stanley estimates humanoid robot cost at about $200,000 in 2024, falling to about $150,000 by 2028 and $50,000 by 2050, with lower-income-country costs potentially as low as $15,000 by 2050. SM001
CM019 Goldman Sachs estimated that the global humanoid-robot market could reach at least $6 billion in 10 to 15 years and up to $154 billion by 2035 in a blue-sky case. SM002
CM020 Goldman Sachs’ bullish scenario depends on product design, use-case, technology, affordability, and public acceptance hurdles being overcome. SM002
CM021 Interact Analysis’ cautious case says humanoid-robot shipments may only reach about 40,000 units and roughly $2 billion of revenue by 2032 despite a much larger theoretical TAM. SM003
CM022 Interact Analysis identifies safety and regulatory concerns as one of the main barriers to humanoid adoption. SM003
CM023 Interact Analysis identifies dexterity and the gap to human productivity as a major barrier to humanoid adoption. SM003
CM024 Interact Analysis identifies high cost driven by custom components as a major barrier to humanoid adoption. SM003
CM025 Interact Analysis questions whether humanoids are the optimal form factor for many applications versus wheeled mobile manipulators. SM003
CM026 Deep Market Insights estimates the China humanoid robot market at $173.54 million in 2025, rising to about $1.69 billion by 2034 at a 28.45% CAGR. SM006
CM027 DataBridge Market Research estimates the China humanoid robot market at $205 million in 2024, rising to about $5.93 billion by 2032 at a 70.81% CAGR. SM007
CM028 China Daily reported a conference estimate that China’s humanoid robot market would grow from 2.76 billion yuan in 2024 to 75 billion yuan by 2029. SM008
CM029 China Daily said industrial manufacturing is likely to lead early humanoid deployment because of its standardized environment. SM008
CM030 Public China humanoid market forecasts differ by several multiples, indicating immature and inconsistent market-boundary definitions. SM006, SM007, SM008
CM031 CNBC reported that people ages 16 to 59 accounted for 61.3% of mainland China’s population in 2023, down from 62% a year earlier. SM012
CM032 CNBC cited UBS analysis that China’s shrinking working-age population is accelerating adoption of automation, robotics, digitalization, and AI. SM012
CM033 China’s retirement-age reform is gradually increasing the retirement age from 60 to 63 for men and from 50/55 to 55/58 for women. SM023
CM034 The World Bank says the impact of automation depends on economic viability as well as technical feasibility, and robots displace routine manual work while productivity gains can offset some job losses. SM013
CM035 VoxDev’s China evidence says a one-standard-deviation increase in robot exposure reduced employment probability by 5 percentage points and hourly wages by about 8%. SM014
CM036 VoxDev found that robot exposure in China pushes younger workers toward training and older workers toward early retirement. SM014
CM037 Agility Robotics and GXO announced the industry’s first formal commercial humanoid deployment and first humanoid Robots-as-a-Service agreement in June 2024. SM017
CM038 The GXO deployment used Digit for repetitive tote-moving tasks in a live warehouse and integrated the robots with existing automation. SM017
CM039 Amazon removed Just Walk Out technology from U.S. Fresh stores and replaced it with smart carts that preserve line-skipping convenience while improving real-time spend visibility. SM018, SM019
CM040 Amazon’s physical grocery rollout showed that even well-funded retail-automation systems can be redesigned or scaled back when economics or customer experience disappoint. SM018, SM019
CM041 UBTech’s humanoid product and service revenue grew from RMB35.6 million in 2024 to RMB820.6 million in 2025, becoming 41% of revenue. SM020, SM021
CM042 UBTech reported total 2025 revenue of RMB2.001 billion, gross margin of 37.7%, and a net loss of RMB789.8 million. SM021
CM043 Yicai reported that China’s robotics sector raised RMB23.2 billion from January to May 2025 versus RMB20.9 billion in all of 2024, and 87% of the new funding went to embodied AI. SM022
CM044 Yicai reported that investors still say embodied-AI robotics has not yet found a core, large-scale commercial application. SM022
CM045 The fact that online retail already accounts for 26.8% of China’s retail sales means e-commerce and fulfillment automation are important substitutes or complements to in-store humanoid deployment. SM015, SM024
CP001 The relevant competitive set for Galbot spans direct humanoid peers, auto-backed or public-company entrants, model-layer competitors, and labor or fixed-automation substitutes. SP015, SP016, SP024
CP002 AgiBot was founded in 2023 in Shanghai by former Huawei engineers. SP001, SP002
CP003 AgiBot publicly markets the A2 full-size humanoid, G1 industrial robot, X2 compact humanoid, and D1 quadruped. SP001, SP002
CP004 Omdia-based coverage cited by TrendForce and DirectIndustry ranks AgiBot first globally in 2025 humanoid shipments at roughly 5,100 units and 39% share. SP016, SP017
CP005 AgiBot said it reached its 10,000th robot production milestone in March 2026 after moving from 5,000 to 10,000 units in about three months. SP001, SP017
CP006 Unitree was founded in 2016 in Hangzhou and ships products to more than 30 countries. SP003, SP004
CP007 Unitree's public G1 price point is $13,500 and the robot is described at roughly 35 kilograms, 130 centimeters, 23 degrees of freedom, and a two-hour battery life. SP003, SP005
CP008 Independent market coverage says Unitree claims roughly 5,500 humanoid robots shipped in 2025 while also presenting an IPO-related maturity narrative. SP017, SP018
CP009 Figure positions F.02 for workforce use and F.03 for household use across its Figure 01, 02, and 03 generations. SP006, SP009
CP010 Figure announced more than $1 billion of committed Series C capital at a $39 billion post-money valuation. SP007, SP018
CP011 Figure's Helix stack uses a System 1 and System 2 architecture and sits alongside a BotQ manufacturing narrative. SP006, SP008
CP012 Physical Intelligence describes π0 as a generalist robot foundation model trained on more than 10,000 hours of robot data and controlling eight different robots. SP010, SP011
CP013 Physical Intelligence also points to π0.5 as an update focused on stronger open-world generalization. SP010, SP011
CP014 XPENG says its IRON humanoid sits inside a broader physical-AI stack and targets mass production by the end of 2026, with in-store guide use from Q1 2027. SP012, SP013
CP015 UBTech's Walker humanoid line is associated with plans to ramp to roughly 5,000 units in 2026 and 10,000 in 2027. SP014, SP016
CP016 TrendForce characterizes Boston Dynamics' Atlas as beginning commercial deployment in 2026 with an industrial focus. SP016
CP017 External coverage presents 1X as progressing toward home use while deliberately limiting physical capabilities for safety. SP015
CP018 Galbot's published positioning is full-stack and in-house across dataset, embodied foundation models, and hardware. SP019, SP021
CP019 Galbot claims more than 10 billion embodied data points and a Sim2Real method that pre-trains on synthetic data before fine-tuning on limited real-world data. SP020, SP021
CP020 Galbot publicly markets GraspVLA, TrackVLA, GroceryVLA, and a brain-cerebellum-neural-control architecture. SP020, SP021
CP021 Galbot cites named deployments with CATL factories, Mercedes-Benz, Zeekr, Xuanwu Hospital, and Galbot Store locations across 30 or more cities. SP019, SP021
CP022 Galbot's state-backed investor set likely improves domestic procurement access and policy credibility relative to purely venture-backed peers. SP019, SP020, SP025
CP023 Galbot does not publish a public unit price for G1, leaving enterprise buyers without a transparent ASP benchmark. SP003, SP021
CP024 AgiBot pairs hardware sales with a Powered by AgiBot OEM-platform story rather than only selling finished robots. SP001, SP002
CP025 Figure and Physical Intelligence show that the competitive frontier is shifting toward model and platform depth, not just robot-body engineering. SP007, SP008, SP010, SP024
CP026 The direct humanoid battlefield is bifurcated between Chinese scale players with visible shipment momentum and US peers with much larger valuation support. SP016, SP018, SP024
CP027 Galbot's public customer evidence points primarily to industrial, retail, and healthcare operators rather than hobbyist or research buyers. SP020, SP021
CP028 Unitree is the clearest public low-end price anchor, but its buyer mix and product positioning differ from Galbot's enterprise-grade deployment narrative. SP003, SP021
CP029 AgiBot's shipment-lead story is disputed because Unitree separately claims a roughly 5,500-unit 2025 shipment figure. SP017, SP018
CP030 Chinese humanoid valuations are heavily discounted versus US peers, with Figure at roughly $39 billion versus Galbot around $3 billion. SP007, SP018, SP019
CP031 TechXplore quotes critics arguing that most humanoid robots are still performative rather than functional and that real use cases remain limited. SP015
CP032 Chinese humanoid standards activity and outside legal commentary show that trust and liability questions are becoming formal buying criteria rather than future issues. SP023, SP025
CP033 Trust posture increasingly favors vendors that can show named enterprise deployments plus alignment with emerging safety and standards frameworks. SP021, SP022, SP025
CP034 Switching costs in humanoid deployments are meaningful but not absolute because buyers can multi-home when models, tooling, and task interfaces remain immature. SP015, SP016, SP024
CP035 Distribution power in this market favors companies with automotive, battery, industrial, hospital, or retailer channels rather than standalone robotics labs. SP013, SP019, SP020
CP036 Galbot's moat is strongest in China-specific deployment access and stack integration today, but its long-run durability is only medium if VLA capabilities commoditize and pricing stays opaque. SP015, SP018, SP021, SP024
CI001 Galbot's public funding timeline began with seed, angel, and angel+ rounds in 2023 before scaling into larger institutional rounds from 2024 onward. SI002, SI003
CI002 Galbot raised RMB 1.1 billion in June 2025 in a round led by CATL-linked capital with strategic and state-backed co-investors. SI002, SI005, SI006
CI003 The June 2025 round positioned Galbot as a unicorn valued above $1 billion. SI002, SI005
CI004 Galbot's December 2025 round brought in more than $300 million, took total raised to roughly $800 million, and set a $3 billion valuation. SI001, SI007
CI005 Galbot's March 2026 round added RMB 2.5 billion, led by the National AI Industry Investment Fund with Sinopec, CITIC Investment Holdings, Bank of China, and SAIC Financial Holdings participating. SI003, SI004, SI020
CI006 After the March 2026 financing, Galbot's cumulative disclosed capital was approximately $1.15 billion or more. SI001, SI003, SI004
CI007 Public round descriptions say the new capital is intended for embodied-AI model development, manufacturing scale-up, and commercial expansion. SI001, SI003, SI014
CI008 Public evidence supports a revenue model that includes hardware sales, deployment or integration fees, and recurring service elements. SI010, SI011, SI014
CI009 Galbot Store and pharmacy deployments suggest Galbot may sometimes monetize through managed operations or operator-style economics rather than only one-time robot sales. SI010, SI011, SI013
CI010 Industrial customers such as CATL, Mercedes-Benz, and Bosch-linked partners imply large-account enterprise selling with longer cycles and higher implementation scope. SI006, SI010, SI014
CI011 Healthcare deployments such as Xuanwu Hospital and robot-pharmacy operations introduce service-quality requirements closer to regulated operations than to consumer gadget sales. SI010, SI013
CI012 Public materials do not confirm dataset or model licensing as a separate booked revenue stream for Galbot. SI010, SI011
CI013 Galbot does not disclose a public unit price for G1, leaving ASP and revenue-recognition analysis unresolved. SI010, SI011
CI014 Broader market coverage uses Unitree's $13,500 G1 as a visible low-end humanoid price anchor, but that benchmark is not directly comparable to Galbot's industrial-grade deployments. SI016, SI019
CI015 Galbot's public GTM appears enterprise-led, with traction communicated through named deployment sites and partners rather than broad self-serve acquisition. SI010, SI014
CI016 Public materials do not disclose CAC, payback period, net revenue retention, or other direct sales-efficiency metrics. SI001, SI010, SI014
CI017 Galbot materials say a single robot can operate a 50-square-meter store and replace three labor shifts over a three-year span. SI011, SI012
CI018 At $15 per hour for three eight-hour shifts across 365 days, Galbot's labor-replacement claim implies roughly $131,400 of annual labor value per fully utilized robot. SI011, SI012
CI019 Pharmacy deployment coverage cites a 99.5% medication-handling success rate, indicating high task reliability but not disclosing corresponding revenue. SI013, SI020
CI020 Public traction indicators include 30-plus-city retail presence, 100-plus pharmacy or store deployments, and several thousand cumulative industrial orders. SI001, SI013, SI014
CI021 Orders and deployment counts cannot be translated cleanly into ARR or recognized revenue because delivery schedules, cancellations, and acceptance criteria are not disclosed. SI001, SI010, SI014
CI022 Galbot's likely cost structure includes bill of materials, actuators, batteries, sensors, compute, installation, and field maintenance rather than only software hosting. SI019, SI022, SI023
CI023 Galbot does not disclose gross margin, and industry context suggests a 20-40% hardware robotics band is plausible but unverified for the company. SI017, SI022, SI023
CI024 Working capital is likely meaningful because robots, parts, and deployment services must be financed before cash collection fully catches up. SI022, SI023
CI025 Manufacturing scale-up after the 2026 financing likely increases capex needs if Galbot expands in-house production capacity. SI003, SI022
CI026 With about $1.15B+ of disclosed capital raised, Galbot appears adequately capitalized for near-term scale-up even without public profitability data. SI001, SI003, SI020
CI027 Galbot's burn rate is undisclosed, but a hardware AI company at this stage could plausibly burn $5-20 million per month depending on manufacturing pace and R&D intensity. SI016, SI022, SI023
CI028 That burn proxy would imply more than 24 months of runway after the March 2026 round only if a large share of prior capital remained available and losses do not widen materially. SI003, SI022, SI023
CI029 State-backed financing likely lowers Galbot's refinancing risk relative to purely venture-backed humanoid peers. SI003, SI024, SI025
CI030 Galbot's roughly $3 billion valuation is far below Figure's $39 billion benchmark, highlighting a major Chinese-versus-US humanoid valuation discount. SI001, SI015, SI018
CI031 CNBC and TechXplore both report skepticism that current humanoid deployments have yet proven broad buyer depth or practical use-case breadth. SI015, SI017
CI032 Galbot does not publicly disclose revenue, ARR, EBITDA, cash balance, burn, gross margin, customer concentration, or payback. SI001, SI010, SI014
CI033 Revenue quality is promising but unproven because deployment breadth is visible while monetization mix and recognized revenue remain opaque. SI010, SI013, SI014
CI034 Margin improvement depends on manufacturing yield, service efficiency, and utilization rising faster than price compression in a crowded humanoid market. SI017, SI019, SI022
CI035 The highest-priority diligence asks are a dated revenue bridge, gross margin by line, order-to-delivery conversion, service attach rates, burn, runway, and working-capital terms. SI001, SI010, SI017
CI036 Galbot should be underwritten as a capital-intensive physical-AI company rather than a typical asset-light SaaS business. SI003, SI022, SI023
CE001 Galbot positions G1 as an embodied-intelligence worker for repeated indoor pick, carry, scan, sort, and delivery workflows in retail, pharmacy, warehouse, and factory settings. SE001, SE004
CE002 G1 combines a dual-arm upper body with a wheel-foot mobility structure, indicating a design optimized for stable indoor navigation plus human-space reach rather than pure bipedal locomotion. SE001, SE002
CE003 Official Galbot materials list G1 at 1730 mm height with 650 mm torso lift. SE001, SE002
CE004 Official Galbot materials list 710 mm arm length, a 0–2100 mm vertical workspace, and 5 kg dual-arm payload for G1. SE001, SE002
CE005 Official Galbot materials list a 48V 30Ah lithium battery, up to 10 hours of operating duration, a 6.25 inch touchscreen, and WiFi, Ethernet, USB, and cloud connectivity. SE001, SE002
CE006 Official Galbot materials state IP54 ingress protection and multimodal sensing that includes vision, tactile, and depth inputs. SE001, SE002
CE007 Public specification sheets are not fully harmonized: the official bundle cites approximately 92.5 kg body weight, while secondary reviews have cited 85 kg. SE002, SE006
CE008 Galbot states that one G1 can operate a 50 square meter store footprint, supporting its positioning in compact autonomous retail environments. SE002, SE006
CE009 Galbot launched GraspVLA in January 2025 as an end-to-end embodied AI grasping foundation model. SE009, SE011
CE010 Public materials describe GraspVLA as trained on billions of simulated interactions to improve zero-shot generalization on new objects and tasks. SE009, SE011
CE011 Galbot links its grasping stack to DexGraspNet-scale data, citing 1.3 million grasps across more than 5,000 objects. SE011, SE018
CE012 TrackVLA is described as a navigation and tracking model that can follow people or objects via visual cues, accept voice commands, and resume tracking after temporary visual loss. SE002, SE011
CE013 GroceryVLA is described as a retail-specific manipulation model that can handle deformable snack bags, rigid bottles, and fragile jars in cluttered environments without per-item reprogramming. SE002, SE006
CE014 Galbot describes a brain-cerebellum-neural-control architecture that links multimodal perception to real-time feedback control in an end-to-end embodied stack. SE002, SE011
CE015 Galbot claims to have accumulated more than 10 billion data points and frames that corpus as the largest embodied-intelligence dataset among peers. SE011, SE012
CE016 Galbot's Sim2Real method relies on large-scale synthetic pretraining followed by limited real-world fine-tuning and minimal semantic relabeling. SE008, SE009
CE017 Robotics & Automation News reported that Galbot uses NVIDIA Isaac Sim in its training-simulation pipeline. SE009
CE018 The existence of developer.galbot.com indicates Galbot has at least a public-facing developer and secondary-development surface for integrations. SE003
CE019 Galbot and Bosch launched the BOYIN INNOVATION ALLIANCE joint venture to target industrial embodied-AI applications and high-precision manufacturing scenarios. SE009, SE010
CE020 Galbot and UAES launched the RoboFab initiative to apply embodied AI in automotive manufacturing. SE010, SE024
CE021 Galbot publicly references research collaboration with Peking University and BAAI, signaling outside scientific relationships around embodied AI. SE005, SE011
CE022 Galbot presents itself as a full-stack company spanning data, embodied foundation models, and robotic hardware rather than a hardware-only integrator. SE004, SE011
CE023 Galbot cites third-party competition validation including a gold medal in the 2025 pharmaceutical sorting challenge. SE005, SE011
CE024 Public company materials and coverage also cite a gold medal at the 2025 World Humanoid Robot Games Robot Skills Competition with 336 points, 160 ahead of the runner-up. SE005, SE024
CE025 Public reporting says industrial settings often demand 99.9% to 99.99% accuracy, a higher bar than the 99.5% medication-handling success publicly cited for pharmacy deployments. SE007, SE012
CE026 ChinaTechNews reports that Galbot G1 achieved 99.5% medication-handling success in Beijing pharmacy use. SE007
CE027 Independent coverage says Galbot has more than 10 pharmacy deployments in Beijing and can sustain 24/7 operation in those settings. SE006, SE007
CE028 Galbot leadership has publicly said that broad commercial rollout of humanoid robots in factories is achievable within roughly two years. SE008, SE012
CE029 Retail and pharmacy rollout plans moved from 10-plus operating sites toward a 100-plus-site ambition, indicating management sees repeatability in the current deployment template. SE006, SE024
CE030 Bosch and UAES partnerships show Galbot's industrial roadmap is being pursued through partner-backed factory access rather than purely greenfield direct sales. SE009, SE010, SE024
CE031 China's March 2026 humanoid robot standards create a more formal compliance baseline for companies such as Galbot. SE013, SE014
CE032 China's May 2026 robot digital-ID regime requires companies to register robots using 29-digit codes. SE013, SE016
CE033 Legal analysis of humanoid robots identifies unresolved liability, autonomy, and data-privacy exposure that is relevant to Galbot's deployments even if not specific to Galbot alone. SE015, SE017
CE034 An adverse report states Galbot has not publicly explained how patient personally identifiable health information is secured in pharmacy workflows. SE007, SE017
CE035 IP54 protection is a meaningful basic durability signal but does not by itself amount to detailed medical, cleanroom, or harsh-factory certification. SE001, SE017
CE036 Compared with competitors such as Physical Intelligence and Figure, Galbot currently offers less public developer and research transparency even while claiming a similarly full-stack embodied-AI ambition. SE003, SE019, SE020, SE021
CE037 Galbot's moat appears to rely more on in-house data loops, deployment access, and manufacturing partnerships than on a publicly legible patent or open-research corpus. SE005, SE010, SE011
CE038 The current public record supports meaningful pilot and early commercial traction, but independent fleet reliability, failure, and service-economics data remain too thin to fully validate roadmap credibility. SE022, SE023, SE025
CU001 Galbot's customer model spans three role patterns: enterprises buy and pay for robots, frontline staff use them in workflow, and in some retail formats Galbot itself acts as operator as well as vendor. SU001, SU007, SU008
CU002 All major public Galbot deployments and named customer references are China-centered as of the run date. SU003, SU004, SU005, SU019
CU003 Galbot's public customer base spans at least four verticals: industrial manufacturing, healthcare/pharmacy, retail/convenience, and warehouse/logistics. SU001, SU004, SU005, SU013
CU004 CATL is both a strategic investor and a customer anchor for Galbot's industrial business. SU001, SU002, SU023
CU005 Galbot said in late 2025 that it had cumulative orders for several thousand units from industrial clients led by CATL, Toyota, and BAIC Group. SU001, SU013
CU006 TechNode reported that Galbot robots were operating at local Mercedes-Benz and Zeekr factories. SU002
CU007 2026 coverage linked SAIC Motor and BAIC Group to Galbot's industrial customer or order narrative. SU003, SU004
CU008 Bosch-linked partnerships act as both validation and channel expansion routes into factory automation deployments. SU010, SU011, SU025
CU009 UAES-linked RoboFab activity extends Galbot's reach into automotive manufacturing workflows, even though public fleet counts are not disclosed. SU003, SU025
CU010 Galbot publicly named Xuanwu Hospital as a healthcare collaboration covering patient rooms, pharmacies, and hospital guidance systems. SU001
CU011 Independent coverage says Galbot had 10+ pharmacies operating in Beijing with 99.5% medication-handling success and 24/7 operation. SU005, SU006
CU012 Galbot said its Galbot Store retail footprint had expanded to 30+ cities nationwide by December 2025. SU001
CU013 By March 2026, secondary coverage said Galbot had 100+ retail units across 20+ cities, including Galaxy Space Capsule convenience formats. SU004
CU014 Galaxy Space Capsule-style convenience stores function as a consumer-facing reference deployment for Galbot's humanoid retail model. SU004, SU006
CU015 Galbot claimed stable 24/7 operations for over a year in autonomous warehouse settings. SU001, SU013
CU016 The strongest publicly attributable customer proofs are CATL, Xuanwu Hospital, Beijing pharmacy sites, BAIC and Toyota order mentions, and Galbot's own retail network. SU001, SU004, SU005
CU017 A significant portion of Galbot's public customer story still looks like early commercial rollout or controlled pilot scaling rather than mature fleet saturation. SU014, SU015, SU016
CU018 Galbot does not publicly disclose NRR, GRR, logo churn, or renewal-rate metrics. SU001, SU007, SU022
CU019 Galbot also does not publicly disclose typical contract length or renewal structure for enterprise customers. SU001, SU013
CU020 CATL's dual role as both lead investor and leading customer creates a related-party concentration and governance risk. SU001, SU002, SU015
CU021 Industrial manufacturing appears to be Galbot's largest current commercial opportunity and likely its largest revenue pool, based on the several-thousand-unit order claim and the concentration of named logos there. SU001, SU003, SU017
CU022 Galbot's expansion motion appears to combine direct flagship sales, partner-mediated industrial rollout, and self-operated retail references. SU001, SU004, SU025
CU023 Customer evidence quality is strongest where Galbot or credible press names a specific institution and workflow, and weakest where a logo appears only in generalized profile coverage. SU001, SU002, SU005
CU024 Galbot's current public footprint is geographically concentrated in China even where the customer list spans multiple cities and verticals. SU004, SU005, SU018, SU019
CU025 Vertical diversity in healthcare and retail somewhat offsets concentration risk, but it does not eliminate the company's heavy dependence on industrial accounts for scaled order volume. SU001, SU004, SU005
CU026 Because public retention metrics are absent, durability must be inferred from operational continuity, strategic partnerships, and repeat rollout signals rather than from cohort data. SU013, SU022
CU027 CATL's investor-customer alignment likely increases Galbot's switching costs and lock-in relative to a purely arms-length pilot relationship. SU001, SU002
CU028 Bosch and UAES partnerships provide a plausible land-and-expand channel into larger factory networks if initial validations convert into standardized deployments. SU010, SU011, SU025
CU029 The move from 10+ pharmacies toward a 100+ rollout ambition suggests Galbot is testing a multi-site replication playbook rather than one-off showcase installations. SU004, SU005, SU006
CU030 Even if accurate, the public claim of several thousand industrial orders remains early relative to the scale of market opportunity and manufacturing ambition implied by sector narratives. SU001, SU014, SU017
CU031 Independent adverse coverage in 2026 argues that humanoid-robot demand still lags sector capacity because practical buyer use cases remain limited. SU014, SU015
CU032 Outside the pharmacy success rate and long-run operations claim, Galbot has published very few independently auditable customer outcome metrics. SU005, SU013, SU014
CU033 Galbot's company-operated retail formats provide useful reference-customer evidence, but they are weaker than independent third-party logos for assessing concentration and renewal quality. SU004, SU006, SU008
CU034 Galbot's partner page and JV news flow indicate an ecosystem-assisted GTM motion rather than a pure reseller-led or pure direct-sales model. SU025, SU026
CU035 By the run date, Galbot's named public customers are concentrated in large Chinese industrial accounts and public-service healthcare contexts rather than a broad SMB base. SU001, SU003, SU005
CU036 BAIC, SAIC, and Toyota are important logos, but their public evidence mostly comes from financing and profile coverage rather than detailed deployment case studies. SU001, SU003, SU023
CU037 Mercedes-Benz and Zeekr are useful proof-of-interest logos, but their evidence quality is lower because the public record is limited to secondary profile reporting. SU002
CU038 Public sources do not disclose top-customer revenue share, so concentration risk cannot be quantitatively bounded from the outside. SU001, SU022
CU039 Claims of 24/7 operations for over a year are positive retention proxies but do not substitute for actual renewal, expansion, or contract-quality data. SU013, SU022
CU040 There is no strong public evidence of materially international customer traction or scaled non-China deployments as of June 2026. SU007, SU022, SU026
CR001 China’s March 2026 humanoid robot standard system formalized a national compliance framework spanning safety, ethics, core technologies, and testing, raising the baseline for every domestic manufacturer. SR003, SR004, SR005, SR032
CR002 China’s May 2026 digital-ID regime makes registration a practical market-access requirement for humanoid robots and expands traceability obligations after deployment. SR002, SR004
CR003 The new robot digital-ID rules reportedly require recalls for defective humanoids and prohibit refurbishment or resale of retired units, increasing downside from manufacturing defects. SR002, SR004
CR004 Hill Dickinson argues that humanoid liability remains unsettled because responsibility can shift among the manufacturer, operator, and software provider after an incident. SR001, SR033
CR005 Hill Dickinson also highlights privacy and biometric-data risk because humanoids can process facial, behavioral, and workplace data under uneven cross-border legal regimes. SR001
CR006 Documented robot-safety incidents in automotive and industrial settings show that maintenance or control failures can cause serious human injury even before humanoids become fully autonomous. SR001, SR009
CR007 Hill Dickinson cites a reported AgiBot malfunction that struck a refrigerator and nearly hit an employee, illustrating that near-miss evidence is already surfacing in Chinese humanoid deployments. SR001
CR008 Geopolitical and export-control exposure remains material for Chinese humanoid firms because advanced chips, overseas markets, and perception of strategic technology are politically sensitive. SR028, SR030, SR031
CR009 The embodied-AI stack is converging around VLA-like model approaches, which increases the probability of IP disputes or costly differentiation battles. SR006, SR009
CR010 Galbot’s founder He Wang is both founder-CEO and a Peking University professor, concentrating strategic, technical, and public-facing responsibilities in one key individual. SR010, SR012
CR011 Galbot presents itself as a full-stack embodied-AI company spanning proprietary models, hardware, data, and deployment systems rather than as a single-use robot vendor. SR010, SR022
CR012 Humanoid scale-up requires coordinated sourcing and integration of actuators, sensors, processors, batteries, and end-effectors, making manufacturing complexity a core operational risk. SR006, SR009
CR013 Industrial deployment standards imply that factory humanoids must approach extremely high task accuracy and uptime before replacing multiple human shifts economically. SR007, SR019
CR014 TechXplore’s June 2026 reporting argues that Chinese firms can build humanoids at scale faster than they can persuade buyers to adopt them, making demand formation a first-order risk. SR007
CR015 Associated Press coverage from late 2025 captured continuing skepticism that many humanoid demos remain performative rather than commercially functional. SR026
CR016 Deloitte warns that hallucinations, perception errors, and software faults in physical AI can create real-world safety incidents rather than purely digital mistakes. SR006, SR001
CR017 Connected robot fleets create cybersecurity and unauthorized-access risk because compromise can affect both data security and physical human safety. SR006, SR001
CR018 Galbot G1 deployments place a 48V 30Ah lithium battery pack near users and staff, so battery integrity and thermal management are part of the operational risk stack. SR015, SR021
CR019 Tactile sensing remains a bottleneck for many human-like tasks, which limits how quickly humanoids can move from demos to general-purpose work. SR009, SR019
CR020 Galbot’s CATL relationship concentrates both commercial demand and financing because the battery giant has been described as both a major investor and a prominent deployment reference. SR012, SR022, SR024
CR021 Galbot’s Bosch-related joint-venture and investment links expand manufacturing and distribution options but also introduce partner-governance and term-reset risk. SR016, SR018
CR022 State-backed investors and banks can improve procurement access and resilience, but they also increase political-dependency risk if policy priorities shift. SR011, SR013, SR014
CR023 Automation World reporting shows Galbot integrating NVIDIA Jetson Thor and Isaac-related tooling, which ties some development workflows to U.S.-linked compute ecosystems. SR027, SR028
CR024 Embodied-AI training remains dependent on simulation and cloud-scale compute even for hardware-first companies, leaving Galbot exposed to platform, cost, and availability shocks. SR006, SR027
CR025 TrendForce’s shipment and market-share analysis suggests Chinese supply chains are deep, but concentration within that ecosystem still creates substitution risk if controls tighten. SR020, SR030
CR026 Galbot does not publicly disclose audited revenue or detailed financial statements, limiting confidence in the current valuation and burn profile. SR008, SR010
CR027 Galbot’s March 2026 round was publicly described as more than $300 million at a roughly $3 billion valuation. SR011, SR013, SR022
CR028 Coverage of Galbot’s 2025 financing indicates the company had already raised roughly $800 million before the 2026 round, underscoring the capital intensity of the category. SR012, SR016, SR024
CR029 Galbot’s $3 billion mark still sits far below Figure AI’s disclosed $39 billion post-money valuation, implying either upside optionality or a China-specific risk discount. SR008, SR023
CR030 Humanoid robotics remains capex-heavy because productization requires sustained R&D, hardware iteration, software training, and field support before margins are proven. SR006, SR008, SR007
CR031 The “replace three shifts” industrial value proposition only works if hardware reliability, support costs, and deployment uptime hold under real production conditions. SR019, SR021, SR007
CR032 The digital-ID regime increases recall downside because manufacturing defects can now trigger traceable corrective action and resale restrictions. SR002, SR004
CR033 Galbot’s full-stack architecture reduces dependence on outside vendors for core models and hardware design, partially mitigating platform and supplier risk. SR010, SR022
CR034 Public deployment references span industrial, retail, healthcare, and pharmaceutical settings, which partially reduces single-vertical demand concentration. SR015, SR017, SR022
CR035 State backing can cushion funding volatility and improve market access, but it does not eliminate execution or commercial demand risk. SR011, SR014
CR036 Simulation-led training can reduce the amount of costly real-world data collection required before deployment, though it cannot fully replace field validation. SR006, SR027
CR037 A clearer national standards framework can gradually reduce regulatory ambiguity even while near-term compliance costs rise. SR003, SR005
CR038 If CATL meaningfully reduces orders or investment support, Galbot would likely face simultaneous revenue, signaling, and financing pressure. SR012, SR022, SR024
CR039 If Galbot cannot demonstrate safe digital-ID-compliant field performance, regulatory clearance and commercial expansion could stall at the same time. SR002, SR003, SR006
CR040 The risk profile is cumulative: tighter regulation, unproven demand, and customer concentration can amplify each other instead of remaining isolated issues. SR001, SR007, SR020
CR041 NIST says its AI Risk Management Framework is intended to help organizations manage risks to individuals, organizations, and society associated with AI and to incorporate trustworthiness considerations into the design, development, use, and evaluation of AI systems. SR034
CV001 Galbot’s March 2026 financing was publicly described as more than $300 million at an approximately $3 billion valuation. SV006, SV007, SV009
CV002 Coverage of Galbot’s 2025 financing indicates the company had already raised roughly $800 million before the 2026 round, making cumulative capital raised roughly $1.15 billion or more. SV011, SV014, SV016
CV003 Galbot’s investor base includes large state-linked institutions and industrial names, which can improve policy access and domestic procurement credibility. SV006, SV007, SV008
CV004 Galbot presents itself as a full-stack embodied-AI company rather than a pure hardware assembler. SV012, SV013
CV005 Official materials indicate Galbot has amassed more than 10 billion data points and multiple embodied-AI models, supporting the claim of a data and software moat. SV012, SV013
CV006 Publicly cited deployments include CATL factories, healthcare sites, and retail/pharmacy environments, giving Galbot more commercial proof than a lab-only startup. SV009, SV012, SV025
CV007 China’s supply-chain depth and manufacturing base are a structural advantage for domestic humanoid vendors that can iterate hardware more quickly than many foreign rivals. SV004, SV005
CV008 TrendForce reported that China accounted for roughly 90% of global humanoid robot shipments in 2025, reinforcing the importance of domestic scale advantages. SV004, SV005
CV009 Founder-CEO He Wang’s Stanford and Peking University credentials strengthen Galbot’s technical credibility with investors and partners. SV011, SV012
CV010 CATL is both a commercial reference and a concentration risk because one counterparty influences demand signaling and financing confidence at the same time. SV009, SV011, SV016
CV011 Galbot’s $3 billion valuation is not anchored to disclosed revenue, audited margin, or public financial statements. SV001, SV012
CV012 TechXplore’s June 2026 reporting argues that demand still lags manufacturing ambition in humanoids, making revenue-ramp assumptions fragile. SV003
CV013 Figure AI’s official Series C announcement put that U.S. peer at a $39 billion post-money valuation, creating a sharp headline gap versus Galbot’s $3 billion mark. SV002, SV029
CV014 The valuation gap with U.S. peers can reflect not only upside potential but also governance, liquidity, and geopolitical discounts applied to Chinese humanoid names. SV001, SV013
CV015 Public evidence still does not disclose Galbot’s burn rate, gross margin, unit economics, or audited revenue trajectory. SV001, SV012
CV016 The CATL relationship creates related-party style concentration risk because one prominent partner influences both commercial optics and investor narrative. SV009, SV011
CV017 Bosch-linked partnerships can accelerate manufacturing and go-to-market execution, but they also introduce partner-term and strategic-priority risk. SV014, SV015
CV018 China’s standards and digital-ID frameworks tighten the operating environment, which can add compliance cost before commercialization reaches steady scale. SV017, SV023, SV024
CV019 Deloitte’s physical-AI analysis implies that safety, cyber, and perception failures can slow adoption and increase liability for embodied-AI vendors. SV017, SV018
CV020 Convergence toward similar VLA-style and full-stack approaches raises the risk that differentiation narrows faster than current valuations imply. SV017, SV018
CV021 Unitree’s published G1 price point shows that aggressive pricing pressure can emerge quickly in Chinese humanoids even before premium use cases are fully stabilized. SV019, SV005
CV022 AgiBot’s visibility supports the view that Galbot competes in a crowded domestic field rather than owning a uniquely open category. SV020, SV005
CV023 XPENG’s robotics activity widens the comparator set beyond startups and reminds investors that capital can also flow to better-disclosed public competitors. SV021, SV026
CV024 Physical Intelligence represents the competing thesis that generalist robot value may accrue to foundation-model platforms rather than to one hardware integrator. SV022
CV025 Because Galbot lacks disclosed revenue and margin inputs, the comparable set must mix private rounds, public comps, and milestone-based reference points rather than rely on one clean multiple. SV001, SV004, SV026
CV026 A bull case for Galbot assumes Chinese industrial humanoid leadership compounds into at least several hundred million dollars of revenue by 2028 and supports a $25 billion to $35 billion value range. SV004, SV006, SV009
CV027 A base case assumes Galbot wins meaningful scale in two to three verticals, develops revenue visibility by 2027, and supports a $10 billion to $15 billion value range. SV004, SV006, SV009
CV028 A bear case assumes commoditization, regulatory drag, or CATL retrenchment and points to a $1 billion to $1.5 billion downside range. SV001, SV003, SV017
CV029 Given the current disclosure gap and concentration profile, the evidence supports a research-more recommendation rather than a clean buy call at $3 billion. SV001, SV011, SV015
CV030 Unknown preferences, seniority, and dilution overhead matter because the post-money headline does not reveal common-equity entry quality. SV006, SV007
CV031 A four-to-six-year hold period is more realistic than a near-term exit because commercialization maturity still lags the financing narrative. SV001, SV003, SV025
CV032 Boston Dynamics and Hyundai show that well-capitalized incumbents are also commercializing humanoids, reducing any scarcity premium for a private Galbot round. SV027, SV030, SV031, SV032
CV033 Reuters and Figure’s own materials show that category leaders can still attract very large funding rounds at much richer valuations than Galbot commands today. SV028, SV029, SV033
CV034 China market leadership can support scale advantages for Galbot even if overseas investors apply a lower valuation multiple to Chinese robotics firms. SV004, SV005, SV001
CV035 Financial opacity is the single largest reason to treat the current mark as stretched rather than obviously attractive. SV001, SV012
CV036 If audited revenue, unit economics, and customer concentration data validate the current narrative, a stretched valuation could move closer to fair. SV006, SV011, SV012
CV037 If digital-ID compliance or privacy controls fail in healthcare-style deployments, valuation downside would widen quickly because both policy and demand confidence would suffer. SV017, SV023, SV024
CV038 The most important final diligence items are audited revenue, unit P&L, CATL contract terms, actual delivery schedules, burn rate, IP freedom to operate, healthcare privacy posture, and cap-table structure. SV006, SV011, SV012, SV017
CV039 Galbot’s deployment breadth across industrial, retail, and healthcare settings supports the core thesis that the company is beyond the pure prototype phase. SV009, SV012, SV025
CV040 The anti-thesis remains that valuation has outrun public proof on revenue, margins, and concentration-adjusted demand quality. SV001, SV003, SV015
来源
编号出版方标题引文
SO001 Galbot Galbot-Official Website Galbot ... serves various industries and every home with embodied AGI robots.
SO002 Galbot Galbot About
SO003 Galbot Galbot web application bundle Galbot operates R&D centers in Beijing, Shenzhen, Suzhou, and Hongkong, and has established joint laboratories/research centers with Peking University, Xuanwu Hospital, and Beijing Zhongguancun College.
SO004 Peking University CFCS He Wang | Faculty Dr. He Wang ... is also the director of PKU-Galbot joint lab of embodied AI.
SO005 Crunchbase News June Hits 3-Year High In Unicorn Births Across AI, Robotics And More Galaxy Bot ... raised a $153 million funding led by Contemporary Amperex Technology. The 2-year-old Beijing-based company was valued at $1 billion.
SO006 OFweek Galbot Secures Record-Breaking $150 Million in New Funding, CATL Leads Investment Galbot announced on June 23 that it has successfully closed a new funding round, raising RMB 1.1 billion.
SO007 Exportsemi CATL Leads with $1.1 Billion Investment, Can Galaxy Universal Robots Propel Embodied AI Commercialization? In March this year, the company unveiled the world's first humanoid robot smart retail solution.
SO008 Robotics & Automation News Galbot raises $151 million to scale embodied AI humanoid robots, partners with Bosch investment arm Galbot ... has raised $151 million in a funding round led by battery giant CATL and Puquan Capital, bringing its total investment to more than $330 million since its founding in 2023.
SO009 Baidu Encyclopedia Beijing Galbot Co., Ltd. It was founded in May 2023, with its registered address at ... Haidian District, Beijing. Its legal representative is Yao Tengzhou.
SO010 Baidu Encyclopedia Yao Tengzhou
SO011 CnEVPost CATL teams with Galbot to scale humanoid robots in battery factories The Galbot S1 features a 50-kilogram dual-arm payload capacity ... The robot has formally entered CATL's smart production line.
SO012 Gasgoo CATL, Galbot partner to scale embodied AI robots for industrial deployment The Galbot S1 has already moved into real-world manufacturing operations ... with a dual-arm payload capacity of up to 50 kilograms.
SO013 The Robot Report Galbot picks up $153M to commercialize G1 semi-humanoid The semi-humanoid mobile manipulator ... is designed to automate inventory, replenishment, delivery, and packaging.
SO014 PR Newswire Galbot Secures Over $300 Million in New Funding, Breaking Records with $3 Billion Valuation in China’s Humanoid Robot Sector This round ... sets new records ... With this investment, the company's valuation has reached $3 billion.
SO015 KrASIA Bubble or breakthrough? China’s humanoid robotics race faces reality check The sector's path to commercialization remains murky.
SO016 MERICS Embodied AI: China’s ambitious path to transform its robotics industry China’s humanoids still lack precision and dexterity ... For commercial viability, the costs would have to fall by at least half.
SO017 U.S.-China Economic and Security Review Commission Humanoid Robots Many other aspects of its stated goals, however, are vague and susceptible to multiple interpretations.
SO018 NVIDIA Developer Blog Spotlight: Galbot Builds a Large-Scale Dexterous Hand Dataset for Humanoid Robots Using NVIDIA Isaac Sim DexGraspNet contains 1.32 million ShadowHand grasps on 5,355 objects.
SO019 arXiv GraspVLA: a Grasping Foundation Model Pre-trained on Billion-scale Synthetic Action Data We curate SynGrasp-1B, a billion-frame robotic grasping dataset generated in simulation.
SO020 arXiv TrackVLA: Embodied Visual Tracking in the Wild We construct an Embodied Visual Tracking Benchmark and collect 1.7 million samples.
SO021 Galbot Galbot S1
SO022 Aparobot Galbot G1: The Humanoid Robot Revolutionizing Retail with Award-Winning Precision Already deployed in over ten unmanned pharmacies across Beijing, Galbot G1 operates 24/7.
SO023 ChinaTechHub China Unveils the World’s First Robot-Run Bodega Galbot quickly expanded to another location at Beijing’s Summer Palace.
SO024 GlobeNewswire Boyuan Capital (investment platform under Bosch Group) and Galbot Forged JV The joint venture will focus on industrial applications with Embodied AI in high-precision manufacturing.
SO025 The Robot Report Galbot brings in $300M to scale mobile manipulator deployments This brought the company’s total funding to $800 million ... and brought Galbot’s valuation to $3 billion.
SM001 Morgan Stanley Humanoids: A $5 Trillion Market By 2050, about 90% of humanoids ... will likely be used for repetitive, simple, and structured work—primarily industrial and commercial purposes.
SM002 Goldman Sachs Research Humanoid robot: The AI accelerant Goldman Sachs Research estimates that the global market for humanoid robots may reach at least US$6bn in 10-15 years ... up to US$154bn by 2035E in a blue-sky scenario.
SM003 The Robot Report Despite the hype, Interact Analysis expects humanoid adoption to remain slow The market intelligence specialist predicts market growth will be relatively slow, reaching over 40,000 units by 2032 with a total market revenue of about $2 billion.
SM004 Fortune Business Insights Warehouse Robotics Market Size, Share Report | 2026-2034 The global warehouse robotics market size was valued at USD 6.51 billion in 2025 and is projected to grow ... to USD 25.41 billion by 2034.
SM005 Grand View Research Warehouse Robotics Market Size & Trends Report, 2030
SM006 Deep Market Insights China Humanoid Robot Market Size, Trends & Forecast Analysis (2026-2034) As per Deep Market Insights, the China Humanoid Robot Market stood at USD 173.54 Million in 2025 and is anticipated to grow to USD 1688.74 Million by 2034.
SM007 DataBridge Market Research China Humanoid Robot Market Size, Trends and Forecast to 2032 The China Humanoid Robot Market was valued at 205.00 USD Million in 2024 ... projected market size 5,928.73 USD Million in 2032.
SM008 China Daily Humanoid robot industry gains momentum, boosting China’s economy China's market scale of the humanoid robot industry is predicted to reach 2.76 billion yuan in 2024 and 75 billion yuan by 2029.
SM009 MarketsandMarkets Global Service Robotics Market Size Report 2024 - 2029 The service robot market is projected to reach USD 98.65 billion by 2029 from USD 47.10 billion in 2024, at a CAGR of 15.9%.
SM010 China Justice Observer China Unveils Five-Year Plan for Robotics Industry By 2025, ... the annual growth rate of the robot industrial revenue is expected to exceed 20 percent and the current intensity of industrial robots to be doubled.
SM011 International Federation of Robotics Global Robot Density in Factories Doubled in Seven Years China took third place in 2023 ... with a high robot density of 470 robots per 10,000 employees.
SM012 CNBC China’s working age population is shrinking People ages 16 to 59 accounted for 61.3% of mainland China’s population last year, down from 62% the prior year.
SM013 World Bank Future Jobs: Robots, Artificial Intelligence, and Digital Platforms in East Asia and Pacific The extent to which new technologies impact jobs depends not only on their technical feasibility but also on the economic viability of adopting the technologies.
SM014 VoxDev Will robots replace workers? Lessons from China A one standard deviation increase in robot exposure reduces employment probabilities by 5 percentage points ... Hourly wages decline by about 8%.
SM015 Gov.cn / Xinhua / NBS China’s retail sales up 3.5 pct in 2024 Total retail sales of consumer goods reached 48.79 trillion yuan ... online retail sales of physical goods ... accounting for 26.8 percent of the total retail sales of consumer goods.
SM016 Market Research Future China Self Checkout In Retail Market Size, Trends | 2035 The China self checkout-in-retail market size was estimated at 330.0 USD Million in 2024 ... projected to grow ... to 1300.0 USD Million by 2035.
SM017 Agility Robotics / GXO GXO Signs Industry-First Multi-Year Agreement with Agility Robotics This agreement ... is both the industry’s first formal commercial deployment of humanoid robots and first Robots-as-a-Service deployment of humanoid robots.
SM018 NBC News Amazon is removing Just Walk Out technology from its Fresh grocery stores in the U.S. Amazon says it will now be replaced by smart carts that allow customers to skip the checkout line but also see their spending in real time.
SM019 Forbes Amazon Is Removing Just Walk Out Technology
SM020 Yicai Global China’s Ubtech Pops After Posting 23-Fold Leap in Annual Humanoid Robot Sales Ubtech sold 1,079 embodied artificial intelligence robots taller than 160 centimeters last year, raking in CNY820.6 million.
SM021 Hong Kong Exchanges and Clearing UBTECH Robotics Corp Ltd Annual Results Announcement for the year ended December 31, 2025 Revenue from full-size embodied intelligent humanoid robot products and services grew rapidly by approximately 2,203.7%, from RMB35.6 million ... to RMB820.6 million.
SM022 Yicai Global China’s Robotics Startups Secure More Funding in Five Months Than in All of 2024 China’s robotics sector raised CNY23.2 billion from January to May ... 87 percent of the funding went to companies working on embodied AI.
SM023 China Legal Experts China’s Retirement Age: Latest Updates & Impact The Chinese retirement age will gradually rise, with men from 60 to 63 and women from 50/55 to 55/58.
SM024 Yicai Global Online Sales Have 27% Share of China Retail After More Than Doubling in Nearly a Decade Online shopping accounted for 26.8 percent of all retail sales of consumer goods in 2024, compared with just 10.8 percent in 2015.
SM025 International Federation of Robotics China overtakes USA in robot density The number of operational industrial robots relative to the number of workers hit 322 units per 10,000 employees in the manufacturing industry.
SP001 AgiBot AgiBot official website
SP002 PRNewswire AgiBot Makes Its US Market Debut at CES 2026
SP003 Unitree Robotics Unitree G1 humanoid robot
SP004 Unitree Robotics Unitree Robotics official website
SP005 Unitree Robotics Unitree H1 humanoid robot
SP006 Figure AI Figure company overview
SP007 Figure AI Figure announces Series C
SP008 Figure AI Figure Helix
SP009 Figure AI Figure AI official website
SP010 Physical Intelligence π0: A Vision-Language-Action Flow Model for General Robot Control
SP011 GitHub Physical-Intelligence/openpi repository
SP012 XPENG XPENG at CVPR 2026
SP013 XPENG XPENG AI Day 2025
SP014 UBTech Robotics UBTech Robotics official website
SP015 TechXplore China humanoids scale hard but buyers remain limited
SP016 TrendForce Humanoid robot market outlook 2026
SP017 DirectIndustry China humanoid robots market: Unitree, AgiBot, Galbot
SP018 CNBC Chinese humanoid robots are attracting investors but still trade below US peers
SP019 PRNewswire Galbot secures over $300 million in new funding round
SP020 TechNode Humanoid robot maker Galbot raises RMB 2.5 billion
SP021 Galbot Galbot official website
SP022 Robotics & Automation News Why China's new humanoid robot safety standards matter
SP023 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SP024 Deloitte Tech Trends 2025: Physical AI
SP025 SCIO China issues humanoid robot-related standards update
SI001 PRNewswire Galbot secures over $300 million in new funding round
SI002 TechNode Galbot raises RMB 1.1 billion led by CATL-linked capital
SI003 TechNode Humanoid robot maker Galbot raises RMB 2.5 billion
SI004 CnEVPost Galbot secures major state backing
SI005 Yicai Global Chinese robotics startup Galbot bags USD153 million in latest fundraiser
SI006 Robotics & Automation News Galbot raises $151 million to scale embodied AI humanoid robots and partners with Bosch investment arm
SI007 The Robot Report Galbot brings in $300M to scale mobile manipulator deployments
SI008 Rocking Robots Galbot valued at $3 billion as it secures over $300 million in new funding round
SI009 AsiaTechDaily China's Galbot secures $153M and launches humanoid robotics joint venture with Bosch
SI010 Galbot Galbot official website
SI011 Galbot Galbot website JavaScript bundle
SI012 Aparobot Galbot G1: the humanoid robot revolutionizing retail
SI013 ChinaTechNews China introduces AI-powered robot pharmacist Galbot G1 to Beijing pharmacies
SI014 China Daily Galbot expands embodied AI commercial deployments
SI015 CNBC Chinese humanoid robots still trade below US peers
SI016 TrendForce Humanoid robot market outlook 2026
SI017 TechXplore China humanoids scale hard but buyers remain limited
SI018 Figure AI Figure announces Series C
SI019 DirectIndustry China humanoid robots market: Unitree, AgiBot, Galbot
SI020 Xinhua China robotics update with Galbot deployment context
SI021 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SI022 Deloitte Tech Trends 2025: Physical AI
SI023 MDPI Academic review of humanoid and service-robot economics
SI024 SCIO China robotics and AI industrial policy update
SI025 Robotics & Automation News China sets national standards for humanoid robots
SI026 U.S. Securities and Exchange Commission (NVIDIA) NVIDIA Corporation Form 10-K (FY ended January 25, 2026)
SI027 U.S. Securities and Exchange Commission (AMD) Advanced Micro Devices Form 10-K (FY ended December 27, 2025)
SI028 U.S. Securities and Exchange Commission (MongoDB) MongoDB, Inc. Form 10-K (FY ended January 31, 2026)
SI029 Amazon Web Services Fireworks.ai Case Study
SI030 Sacra Fireworks AI revenue, valuation & funding
SI031 Index Ventures Inference is the New Runtime
SI032 Business Wire Fireworks AI Raises $250M Series C
SI033 Tech Funding News Fireworks AI closes $250M at $4B valuation
SE001 Galbot Galbot G1 product page
SE002 Galbot Galbot official JavaScript bundle with embedded product specifications
SE003 Galbot Galbot developer platform
SE004 Galbot Galbot official homepage
SE005 Galbot Galbot about page
SE006 Aparobot Galbot G1: the humanoid robot revolutionizing retail
SE007 ChinaTechNews China introduces AI-powered robot pharmacist Galbot G1 to Beijing pharmacies The company has not revealed how it secures patient personally identifiable health information.
SE008 China Daily Galbot scales embodied AI through Sim2Real
SE009 Robotics & Automation News Galbot raises $151 million to scale embodied AI humanoid robots and partners with Bosch investment arm
SE010 AsiaTechDaily China's Galbot secures $153M, launches humanoid robotics joint venture with Bosch
SE011 PR Newswire Galbot secures over $300 million in new funding round
SE012 TechNode Galbot profile and product development update
SE013 SCIO China Voices: humanoid robot standards update
SE014 Robotics & Automation News China sets national standards for humanoid robots
SE015 Robotics & Automation News Why China's new humanoid robot safety standards matter
SE016 Xinhua China launches digital ID system for robots
SE017 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SE018 MDPI Electronics Academic review of embodied manipulation datasets and control methods
SE019 Physical Intelligence pi0 foundation model launch post
SE020 GitHub OpenPI repository
SE021 Figure Introducing Helix
SE022 TechXplore China's humanoid makers can scale, but buyers remain scarce Use cases are still so limited that demand is not yet matching capacity ambitions.
SE023 Deloitte Tech Trends 2025: physical AI
SE024 CnTechPost Galbot secures major state backing
SE025 TrendForce Humanoid robot market outlook
SE026 GraspNet DexGraspNet project page
SE027 NVIDIA NVIDIA Isaac Sim
SE028 NVIDIA NVIDIA Omniverse platform
SE029 Peking University Peking University official English site
SE030 BAAI Beijing Academy of Artificial Intelligence official English site
SE031 ISO International Organization for Standardization homepage
SE032 MIIT Ministry of Industry and Information Technology of China
SE033 ROS ROS official homepage
SU001 PR Newswire Galbot secures over $300 million in new funding round Galbot said it had secured cumulative orders for several thousand units from industrial clients led by CATL, Toyota, and BAIC Group.
SU002 TechNode Galbot profile and CATL-linked deployment update
SU003 TechNode Humanoid-robot maker Galbot raises RMB 2.5 billion
SU004 CnTechPost Galbot secures major state backing
SU005 ChinaTechNews China introduces AI-powered robot pharmacist Galbot G1 to Beijing pharmacies
SU006 Aparobot Galbot G1: the humanoid robot revolutionizing retail
SU007 Galbot Galbot official homepage
SU008 Galbot Galbot official JavaScript bundle with deployment copy
SU009 China Daily Galbot embodied-AI deployment update
SU010 Robotics & Automation News Galbot raises $151 million to scale embodied AI humanoid robots, partners with Bosch investment arm
SU011 AsiaTechDaily China's Galbot secures $153M, launches humanoid robotics joint venture with Bosch
SU012 Rocking Robots Galbot valued at $3 billion as it secures over $300 million in new funding round
SU013 The Robot Report Galbot brings in $300M to scale mobile manipulator deployments
SU014 TechXplore China's humanoid makers can scale, but buyers remain scarce Use cases are still so limited that demand is not yet matching the sector's production ambitions.
SU015 CNBC China humanoid robots attract investors, but real customers are still emerging
SU016 DirectIndustry eMag China humanoid robots market overview
SU017 TrendForce Humanoid robot market outlook
SU018 Xinhua China launches digital ID system for robots
SU019 SCIO China Voices: humanoid robot standards update
SU021 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SU022 Deloitte Tech Trends 2025: physical AI
SU023 Yicai Global Chinese robotics startup Galbot bags $153 million in latest fundraiser
SU024 Robotics & Automation News China sets national standards for humanoid robots
SU025 Galbot Galbot partner page
SU026 Galbot Galbot about page
SU027 Mercedes-Benz Mercedes-Benz official homepage
SU028 ZEEKR ZEEKR official homepage
SU029 Toyota Toyota Global official homepage
SU030 BAIC Group BAIC Group official English homepage
SU031 SAIC Motor SAIC Motor official English homepage
SU032 Bosch Bosch global official homepage
SU033 UAES UAES official English homepage
SU034 CATL CATL official English homepage
SR001 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SR002 Xinhua China launches digital identity system for humanoid robots
SR003 State Council Information Office China unveils national standard system for humanoid robots
SR004 Robotics & Automation News Why China’s new humanoid robot safety standards matter
SR005 Robotics & Automation News China sets national standards for humanoid robots
SR006 Deloitte Tech Trends 2025: Physical AI
SR007 TechXplore China can build humanoids at scale, but buyers remain hard to find
SR008 CNBC China humanoid robot startups court investors but still trail U.S. peers
SR009 MDPI Electronics Embodied AI and humanoid robot commercialization constraints
SR010 Galbot Galbot official website
SR011 PR Newswire Galbot secures over $300 million in new funding round
SR012 TechNode Galbot deploys robots with CATL and grows embodied AI footprint
SR013 TechNode Humanoid robot maker Galbot raises RMB 2.5 billion
SR014 CnEVPost Galbot secures major state backing in new financing
SR015 ChinaTechNews China introduces AI-powered robot pharmacist Galbot G1 to Beijing pharmacies
SR016 AsiaTechDaily Galbot secures $153M and launches humanoid robotics joint venture with Bosch
SR017 China Daily Galbot expands embodied AI deployment cases
SR018 Robotics & Automation News Galbot raises $151 million and partners with Bosch investment arm
SR019 DirectIndustry e-Magazine China’s humanoid robot market: Unitree, AgiBot, Galbot
SR020 TrendForce China leads humanoid robot commercialization and shipment scale
SR021 Aparobot Galbot G1: the humanoid robot revolutionizing retail
SR022 The Robot Report Galbot brings in $300M to scale mobile manipulator deployments
SR023 Figure AI Figure Series C
SR024 Yicai Global Chinese robotics startup Galbot bags USD153 million in latest fundraiser
SR025 Rocking Robots Galbot valued at $3 billion as it secures over $300 million in new funding round
SR026 U.S. News / Associated Press Humanoid robots take center stage at Silicon Valley summit, but skepticism remains
SR027 Automation World Galbot’s humanoid robot integrates NVIDIA Jetson Thor with potential for manufacturing use
SR028 CNBC Video Nvidia-powered Galbot hedges against U.S. trade risks with a diversified supply chain
SR029 China Biz Insider Galbot deploys heavy-duty humanoid robot at CATL, signaling industrial AI adoption
SR030 U.S.-China Economic and Security Review Commission Humanoid Robots
SR031 Humanoids Daily The GUARD Act: bipartisan bill seeks to ban Chinese robots, threatening the U.S. research baseline
SR032 Robotics & Automation News Why China’s new humanoid robot standards could change the industry
SR033 Hill Dickinson Humanoid robots and the law - preparing for a new era of risk
SR034 NIST AI Risk Management Framework
SV001 CNBC China humanoid robot startups court investors but still trail U.S. peers
SV002 Figure AI Figure Series C
SV003 TechXplore China can build humanoids at scale, but buyers remain hard to find
SV004 TrendForce China leads humanoid robot commercialization and shipment scale
SV005 DirectIndustry e-Magazine China’s humanoid robot market: Unitree, AgiBot, Galbot
SV006 PR Newswire Galbot secures over $300 million in new funding round
SV007 TechNode Humanoid robot maker Galbot raises RMB 2.5 billion
SV008 CnEVPost Galbot secures major state backing
SV009 The Robot Report Galbot brings in $300M to scale mobile manipulator deployments
SV010 Rocking Robots Galbot valued at $3 billion as it secures over $300 million in new funding round
SV011 TechNode Galbot and CATL deployment profile
SV012 Galbot Galbot official website
SV013 Galbot Galbot website application bundle
SV014 AsiaTechDaily Galbot secures $153M and launches humanoid robotics joint venture with Bosch
SV015 Robotics & Automation News Galbot raises $151 million to scale embodied AI humanoid robots, partners with Bosch investment arm
SV016 Yicai Global Chinese robotics startup Galbot bags USD153 million in latest fundraiser
SV017 Hill Dickinson Humanoid robots and the law: preparing for a new legal frontier
SV018 Deloitte Tech Trends 2025: Physical AI
SV019 Unitree Robotics Unitree G1 humanoid robot
SV020 AgiBot AgiBot official website
SV021 XPENG XPENG robotics and embodied intelligence newsroom update
SV022 Physical Intelligence pi0 foundation model announcement
SV023 State Council Information Office China unveils national standard system for humanoid robots
SV024 Xinhua China launches digital identity system for humanoid robots
SV025 Aparobot Galbot G1: the humanoid robot revolutionizing retail
SV026 XPeng Investor Relations XPENG 2025 Annual Report on Form 20-F
SV027 Boston Dynamics Meet the all-new electric Atlas
SV028 Reuters AI robot maker Figure raises $675 million led by Microsoft and Nvidia
SV029 PR Newswire Figure exceeds $1B in Series C funding at $39B post-money valuation
SV030 Hyundai Motor Group Hyundai Motor Group announces AI robotics strategy at CES 2026
SV031 WBUR / Associated Press Hyundai and Boston Dynamics unveil humanoid robot Atlas at CES
SV032 Hyundai Mobis Hyundai Mobis and Boston Dynamics announce global robotics supply chain collaboration
SV033 Robozaps Figure AI review: robots, Helix AI, and complete guide 2026